BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W, Colombel JF, Vermeire S, Travis S, Lindsay JO, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965-990. [PMID: 23040452 DOI: 10.1016/j.crohns.2012.09.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 479] [Article Influence: 53.9] [Reference Citation Analysis]
Number Citing Articles
1 Calafat M, Lobatón T, Mañosa M, Marín L, Caballero N, Larraín M, Cabré E, Domènech E. Therapeutic requirements in active ulcerative proctitis: A single-centre study. Gastroenterol Hepatol 2017;40:663-8. [PMID: 28666605 DOI: 10.1016/j.gastrohep.2017.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, Kim HK, Cheon JH, Im JP, Kim YS. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9 Suppl 1:35-44. [PMID: 26395533 DOI: 10.1586/17474124.2015.1091309] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 13.5] [Reference Citation Analysis]
3 Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. In: Farah CS, Balasubramaniam R, Mccullough MJ, editors. Contemporary Oral Medicine. Cham: Springer International Publishing; 2019. pp. 67-136. [DOI: 10.1007/978-3-319-72303-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Canavese G, Villanacci V, Antonelli E, Cadei M, Sapino A, Rocca R, Daperno M, Suriani R, Di Santo MG, Cassoni P, Bernardini N, Bassotti G. Eosinophilia - associated basal plasmacytosis: an early and sensitive histologic feature of inflammatory bowel disease. APMIS 2017;125:179-83. [PMID: 28120414 DOI: 10.1111/apm.12639] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
5 Ordás I, Domènech E, Mañosa M, García-Sánchez V, Iglesias-Flores E, Rodríguez-Moranta F, Márquez L, Merino O, Fernández-Bañares F, Gomollón F, Vera M, Gutiérrez A, LLaó J, Gisbert JP, Aguas M, Arias L, Rodríguez-Lago I, Muñoz C, Alcaide N, Calvet X, Rodríguez C, Montoro MA, García S, De Castro ML, Piqueras M, Pareja L, Ribes J, Panés J, Esteve M; ENEIDA registry of GETECCU. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry. Am J Gastroenterol 2018;113:1009-16. [PMID: 29713028 DOI: 10.1038/s41395-018-0057-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Luan ZJ, Li Y, Zhao XY, Wang L, Sun YH, Wang SY, Qian JM. Treatment efficacy and safety of low-dose azathioprine in chronic active ulcerative colitis patients: A meta-analysis and systemic review: Low-dose AZA treatment in UC patients. Journal of Digestive Diseases 2016;17:652-9. [DOI: 10.1111/1751-2980.12386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
7 Lovén Wickman U, Yngman-Uhlin P, Hjortswang H, Riegel B, Stjernman H, Hollman Frisman G. Self-Care Among Patients With Inflammatory Bowel Disease: An Interview Study. Gastroenterol Nurs 2016;39:121-8. [PMID: 26166423 DOI: 10.1097/SGA.0000000000000120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
8 Fischer S, Kövesdi E, Magyari L, Csöngei V, Hadzsiev K, Melegh B, Hegyi P, Sarlós P. IL23R single nucleotide polymorphisms could be either beneficial or harmful in ulcerative colitis. World J Gastroenterol 2017; 23(3): 447-454 [PMID: 28210080 DOI: 10.3748/wjg.v23.i3.447] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1-7. [PMID: 26893582 DOI: 10.2147/dhps.s62649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Chen Y, Li H, Lai L, Huang Y, Shen J. Discovery of new long noncoding RNAs associated with ulcerative colitis with a novel general microarray expression data. Life Sci 2021;287:120090. [PMID: 34715141 DOI: 10.1016/j.lfs.2021.120090] [Reference Citation Analysis]
12 Zhang Y, Gao Y, Wang M, Shi L, Liu Y, Yan C, Wang J, Meluleki HJ, Geng W, Wang Y. The fermented soy whey produced by a combined lactic acid bacteria starter shows improved flavor and the function in alleviating dextran sulphate sodium induced colitis in mice. Food Biotechnology 2022;36:113-32. [DOI: 10.1080/08905436.2022.2051539] [Reference Citation Analysis]
13 Iborra M, Pérez-gisbert J, Bosca-watts MM, López-garcía A, García-sánchez V, López-sanromán A, Hinojosa E, Márquez L, García-lópez S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez-gutiérrez C, Barrio J, Cabriada JL, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman HS, Hervás D, Nos P; Spanish Working Group on Crohn’s Disease and Ulcerative Colitis (GETECCU). Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients. J Gastroenterol 2017;52:788-99. [DOI: 10.1007/s00535-016-1274-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
14 Barreiro-de Acosta M, Vallejo N, de la Iglesia D, Uribarri L, Bastón I, Ferreiro-Iglesias R, Lorenzo A, Domínguez-Muñoz JE. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. J Crohns Colitis 2016;10:13-9. [PMID: 26351390 DOI: 10.1093/ecco-jcc/jjv158] [Cited by in Crossref: 92] [Cited by in F6Publishing: 78] [Article Influence: 13.1] [Reference Citation Analysis]
15 Deva Rajoo G, Tan L, Lopez A, Lewindon P, Grover Z. Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis. Dig Dis Sci 2019;64:1929-37. [DOI: 10.1007/s10620-019-05486-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Gálvez-Llompart M, Recio MC, García-Domenech R, Gálvez J. Molecular topology: a strategy to identify novel compounds against ulcerative colitis. Mol Divers 2017;21:219-34. [PMID: 27734189 DOI: 10.1007/s11030-016-9706-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
17 Nishimura S, Yoshino T, Fujikawa Y, Watanabe M, Yazumi S. A rare case of ulcerative colitis exacerbated by VZV infection. Clin J Gastroenterol 2015;8:390-2. [DOI: 10.1007/s12328-015-0613-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Øresland T, Faerden AE. Surgery in the age of biological treatment. Scand J Gastroenterol 2015;50:121-7. [PMID: 25523562 DOI: 10.3109/00365521.2014.972445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
19 Freitas TH, Hyphantis TN, Andreoulakis E, Quevedo J, Miranda HL, Alves GS, Souza MH, Braga LL, Pargament KI, Soczynska JK, Mcintyre RS, Carvalho AF. Religious coping and its influence on psychological distress, medication adherence, and quality of life in inflammatory bowel disease. Braz J Psychiatry 2015;37:219-27. [DOI: 10.1590/1516-4446-2014-1507] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
20 Nazarian A, Bishay K, Gholami R, Scaffidi MA, Khan R, Cohen-Lyons D, Griller N, Satchwell JB, Baker JP, Grover SC, Irvine EJ. Factors Associated with Poor Quality of Life in a Canadian Cohort of Patients with Inflammatory Bowel Disease: A Cross-sectional Study. J Can Assoc Gastroenterol 2021;4:91-6. [PMID: 33855267 DOI: 10.1093/jcag/gwaa014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Manetti N, Bagnoli S, Rogai F, Bonanomi AG, Vannozzi G, Giannotta M, Annese V. Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany. Inflamm Bowel Dis 2016;22:1945-53. [PMID: 27104823 DOI: 10.1097/MIB.0000000000000787] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
22 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Schreiber-Dietrich D, Chiorean L, Cui XW, Braden B, Kucharzik T, Jüngert J, Kosiak W, Stenzel M, Dietrich CF. Particularities of Crohn's disease in pediatric patients: current status and perspectives regarding imaging modalities. Expert Rev Gastroenterol Hepatol 2015;9:1313-25. [PMID: 26377445 DOI: 10.1586/17474124.2015.1083420] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
24 Sullivan KJ, Wei M, Chernetsova E, Hallani S, de Nanassy J, Benchimol EI, Mack DR, Nasr A, El Demellawy D. Value of upper endoscopic biopsies in predicting medical refractoriness in pediatric patients with ulcerative colitis. Hum Pathol. 2017;66:167-176. [PMID: 28652148 DOI: 10.1016/j.humpath.2017.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
25 Beigmohammadi F, Mahmoudi M, Karami J, Ahmadzadeh N, Ebrahimi-Daryani N, Rezaei N. Analysis of Killer Cell Immunoglobulin-Like Receptor Genes and Their HLA Ligands in Inflammatory Bowel Diseases. J Immunol Res 2020;2020:4873648. [PMID: 33015197 DOI: 10.1155/2020/4873648] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Wei ZZ, Li N. Application of confocal laser endomicroscopy in ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2015; 23(12): 1924-1929 [DOI: 10.11569/wcjd.v23.i12.1924] [Reference Citation Analysis]
27 Ribaldone DG, Dileo I, Pellicano R, Resegotti A, Fagoonee S, Vernero M, Saracco G, Astegiano M. Severe ulcerative colitis: predictors of response and algorithm proposal for rescue therapy. Ir J Med Sci 2018;187:385-92. [PMID: 28756540 DOI: 10.1007/s11845-017-1666-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
28 Con D, De Cruz P. Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools. JMIR Mhealth Uhealth. 2016;4:e13. [PMID: 26831935 DOI: 10.2196/mhealth.4874] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
29 Ranjha R, Aggarwal S, Bopanna S, Ahuja V, Paul J. Site-Specific MicroRNA Expression May Lead to Different Subtypes in Ulcerative Colitis. PLoS One 2015;10:e0142869. [PMID: 26569605 DOI: 10.1371/journal.pone.0142869] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
30 Hahnemann M, Dechene A, Kathemann S, Sirin S, Gerken G, Lauenstein T, Kinner S. Diagnostic value of diffusion-weighted imaging (DWI) for the assessment of the small bowel in patients with inflammatory bowel disease. Clinical Radiology 2017;72:95.e1-8. [DOI: 10.1016/j.crad.2016.08.007] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
31 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
32 Sahu P, Kedia S, Vuyyuru SK, Bajaj A, Markandey M, Singh N, Singh M, Kante B, Kumar P, Ranjan M, Sahni P, Panwar R, Sharma R, Das P, Makharia G, Travis SPL, Ahuja V. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment Pharmacol Ther 2021;53:568-76. [PMID: 33440046 DOI: 10.1111/apt.16249] [Reference Citation Analysis]
33 Kim D, Jung JY, Oh HS, Jee SR, Park SJ, Lee SH, Yoon JS, Yu SJ, Yoon IC, Lee HS. Comparison of sampling methods in assessing the microbiome from patients with ulcerative colitis. BMC Gastroenterol 2021;21:396. [PMID: 34686128 DOI: 10.1186/s12876-021-01975-3] [Reference Citation Analysis]
34 Ciccocioppo R, Racca F, Scudeller L, Piralla A, Formagnana P, Pozzi L, Betti E, Vanoli A, Riboni R, Kruzliak P, Baldanti F, Corazza GR. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res 2016;64:191-203. [PMID: 26659090 DOI: 10.1007/s12026-015-8737-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
35 Bosch S, Wintjens DSJ, Wicaksono A, Kuijvenhoven J, van der Hulst R, Stokkers P, Daulton E, Pierik MJ, Covington JA, de Meij TGJ, de Boer NKH. The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis. Dig Liver Dis 2020;52:745-52. [PMID: 32402741 DOI: 10.1016/j.dld.2020.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Kinugasa T, Akagi Y. Status of colitis-associated cancer in ulcerative colitis. World J Gastrointest Oncol 2016; 8(4): 351-357 [PMID: 27096030 DOI: 10.4251/wjgo.v8.i4.351] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
37 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. Journal of Crohn's and Colitis 2013;7:982-1018. [DOI: 10.1016/j.crohns.2013.09.016] [Cited by in Crossref: 486] [Cited by in F6Publishing: 410] [Article Influence: 54.0] [Reference Citation Analysis]
38 Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohns Colitis. 2015;9:164-169. [PMID: 25518057 DOI: 10.1093/ecco-jcc/jju015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 6.3] [Reference Citation Analysis]
39 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
40 Jain S, Kedia S, Bopanna S, Sachdev V, Sahni P, Dash NR, Pal S, Vishnubhatla S, Makharia G, Travis SPL, Ahuja V. Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. J Crohns Colitis. 2017;11:1309-1316. [PMID: 29088461 DOI: 10.1093/ecco-jcc/jjx084] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
41 Matsuoka K, Uemura Y, Kanai T, Kunisaki R, Suzuki Y, Yokoyama K, Yoshimura N, Hibi T. Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. Dig Dis Sci. 2018;63:1910-1919. [PMID: 29450747 DOI: 10.1007/s10620-018-4946-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
42 de Frias Gomes CG, de Almeida ASR, Mendes CCL, Ellul P, Burisch J, Buhagiar T, Attard A, Lo B, Ungaro RC, da Silva Morão BT, Gouveia CF, de Carvalho E Branco JMD, Rodrigues JMMP, Teixeira C, Dias de Castro MFF, Nunes GFD, Brito M, de Sousa Antunes MC, Borralho Nunes PMFB, da Silva Torres JMT. Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis. Inflamm Bowel Dis 2021:izab069. [PMID: 33999195 DOI: 10.1093/ibd/izab069] [Reference Citation Analysis]
43 Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, Panés J, Gomollón F; Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). [Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]. Gastroenterol Hepatol 2013;36:127-46. [PMID: 23433780 DOI: 10.1016/j.gastrohep.2013.01.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
44 Tursi A, Allegretta L, Della Valle N, Hadad Y, Penna A, Pranzo G, Ricciardelli C, Paiano P, Picchio M. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis. Clin Res Hepatol Gastroenterol 2016;40:e61-3. [PMID: 27297910 DOI: 10.1016/j.clinre.2016.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
45 Filipe V, Allen PB, Peyrin-biroulet L. Self-medication with steroids in inflammatory bowel disease. Digestive and Liver Disease 2016;48:23-6. [DOI: 10.1016/j.dld.2015.10.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
46 Kekilli M, Beyazit Y, Tas A, Tunc B, Sayilir A, Ulker A. Atypical pANCA as a marker of indeterminate colitis for the prediction of ulcerative colitis and crohn’s disease. Wien Klin Wochenschr 2013;125:279-82. [DOI: 10.1007/s00508-013-0363-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Armuzzi A, Felice C, Lubrano E, Cantini F, Castiglione F, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Marchesoni A, Vecchi M, Olivieri I. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. Digestive and Liver Disease 2017;49:1298-305. [DOI: 10.1016/j.dld.2017.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
48 Costa Pereira C, Durães C, Coelho R, Grácio D, Silva M, Peixoto A, Lago P, Pereira M, Catarino T, Pinho S, Teixeira JP, Macedo G, Annese V, Magro F. Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease. PLoS One 2017;12:e0169102. [PMID: 28052094 DOI: 10.1371/journal.pone.0169102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
49 Portela F, Dias CC, Caldeira P, Cravo M, Deus J, Gonçalves R, Lago P, Morna H, Peixe P, Ramos J, Sousa H, Tavares L, Vasconcelos H, Magro F, Ministro P. The who-when-why triangle of complementary and alternative medicine use among Portuguese IBD patients. Digestive and Liver Disease 2017;49:388-96. [DOI: 10.1016/j.dld.2016.12.031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
50 Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH. Atypical distribution of inflammation in newly diagnosed ulcerative colitis is not rare. Can J Gastroenterol Hepatol. 2014;28:125-130. [PMID: 24619632 DOI: 10.1155/2014/834512] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
51 Colombel JF, Ordás I, Ullman T, Rutgeerts P, Chai A, O'Byrne S, Lu TT, Panés J. Agreement Between Rectosigmoidoscopy and Colonoscopy Analyses of Disease Activity and Healing in Patients With Ulcerative Colitis. Gastroenterology 2016;150:389-95.e3. [PMID: 26526713 DOI: 10.1053/j.gastro.2015.10.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
52 De Simone B, Davies J, Chouillard E, Di Saverio S, Hoentjen F, Tarasconi A, Sartelli M, Biffl WL, Ansaloni L, Coccolini F, Chiarugi M, De'Angelis N, Moore EE, Kluger Y, Abu-Zidan F, Sakakushev B, Coimbra R, Celentano V, Wani I, Pintar T, Sganga G, Di Carlo I, Tartaglia D, Pikoulis M, Cardi M, De Moya MA, Leppaniemi A, Kirkpatrick A, Agnoletti V, Poggioli G, Carcoforo P, Baiocchi GL, Catena F. WSES-AAST guidelines: management of inflammatory bowel disease in the emergency setting. World J Emerg Surg 2021;16:23. [PMID: 33971899 DOI: 10.1186/s13017-021-00362-3] [Reference Citation Analysis]
53 Lui RNS, Ng SC. The Same Intestinal Inflammatory Disease despite Different Genetic Risk Factors in the East and West? Inflamm Intest Dis 2016;1:78-84. [PMID: 29922661 DOI: 10.1159/000446625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Kump PK, Gröchenig HP, Lackner S, Trajanoski S, Reicht G, Hoffmann KM, Deutschmann A, Wenzl HH, Petritsch W, Krejs GJ. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis. 2013;19:2155-2165. [PMID: 23899544 DOI: 10.1097/mib.0b013e31829ea325] [Cited by in Crossref: 166] [Cited by in F6Publishing: 104] [Article Influence: 20.8] [Reference Citation Analysis]
55 Daperno M, Bortoli A, Kohn A, Politi P, Marconi S, Ardizzone S, Cortelezzi CC, Grasso G, Ferraris L, Milla M, Spina L, Guidi L, Losco A, Inserra G, Sablich R, Morganti D, Bodini G, Comberlato M. Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study. Digestive and Liver Disease 2017;49:997-1002. [DOI: 10.1016/j.dld.2017.05.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
56 Lasson A, Stotzer PO, Öhman L, Isaksson S, Sapnara M, Strid H. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26-32. [PMID: 25008478 DOI: 10.1016/j.crohns.2014.06.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
57 Szakács Z, Csiszár B, Kenyeres P, Sarlós P, Erőss B, Hussain A, Nagy Á, Kőszegi B, Veczák I, Farkas N, Bódis E, Márta K, Szentesi A, Tőkés-Füzesi M, Berki T, Vincze Á, Tóth K, Hegyi P, Bajor J. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol. BMJ Open 2019;9:e026315. [PMID: 30904871 DOI: 10.1136/bmjopen-2018-026315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Tontini GE, Vecchi M, Neurath MF, Neumann H. Advanced endoscopic imaging techniques in Crohn’s disease. J Crohns Colitis. 2014;8:261-269. [PMID: 24080247 DOI: 10.1016/j.crohns.2013.09.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
59 Vieira-Silva S, Sabino J, Valles-Colomer M, Falony G, Kathagen G, Caenepeel C, Cleynen I, van der Merwe S, Vermeire S, Raes J. Quantitative microbiome profiling disentangles inflammation- and bile duct obstruction-associated microbiota alterations across PSC/IBD diagnoses. Nat Microbiol. 2019;4:1826-1831. [PMID: 31209308 DOI: 10.1038/s41564-019-0483-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 15.7] [Reference Citation Analysis]
60 Fron C, Pierry C, Poullenot F, Chabrun E, Subtil C, Capdepont M, Zerbib F, Belleannée G, Laharie D. Endoscopic and histologic response to cyclosporine in ulcerative colitis and their impact on disease outcome: A cohort study. Dig Liver Dis 2016;48:734-9. [PMID: 27052254 DOI: 10.1016/j.dld.2016.03.007] [Reference Citation Analysis]
61 Sampietro GM, Colombo F, Frontali A, Baldi CM, Carmagnola S, Cassinotti A, Dell’era A, Massari A, Molteni P, Dilillo D, Fociani P, Tonolini M, Maconi G, Fiorina P, Corsi F, Bianco R, Nebuloni M, Zuccotti G, Ardizzone S, Foschi D. Totally laparoscopic, multi-stage, restorative proctocolectomy for inflammatory bowel diseases. A prospective study on safety, efficacy and long-term results. Digestive and Liver Disease 2018;50:1283-91. [DOI: 10.1016/j.dld.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
62 Feng T, Chen B, Li L, Huang S, Ben-Horin S, Qiu Y, Feng R, Li M, Mao R, He Y, Zeng Z, Zhang S, Chen M. Serum Interleukin 9 Levels Predict Disease Severity and the Clinical Efficacy of Infliximab in Patients with Crohn's Disease. Inflamm Bowel Dis 2017;23:1817-24. [PMID: 28644181 DOI: 10.1097/MIB.0000000000001172] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
63 Jain S, Kedia S, Sethi T, Bopanna S, Yadav DP, Goyal S, Padhan R, Venigalla PM, Sahni P, Dash NR, Pal S, Makharia G, Travis SPL, Ahuja V. Predictors of long-term outcomes in patients with acute severe colitis: A northern Indian cohort study. J Gastroenterol Hepatol. 2018;33:615-622. [PMID: 28801987 DOI: 10.1111/jgh.13921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
64 Yamakawa K, Yoshino T, Watanabe K, Kawano K, Kurita A, Matsuzaki N, Yuba Y, Yazumi S. Effectiveness of cyclosporine as a treatment for steroid-resistant Cronkhite-Canada syndrome; two case reports. BMC Gastroenterol. 2016;16:123. [PMID: 27716071 DOI: 10.1186/s12876-016-0541-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
65 Philip M, Augustine P, Thomas V, Ramesh GN, Vinayakumar KR, Ramachandran TM, Siyad I, Mukkada RJ, Devi RS, Chettupuzha AP, Jaison VA, Ramesh M, Mahadevan P, Koshy A; Kerala Inflammatory Bowel Disease Study Group. Multi-center prospective survey of inflammatory bowel diseases in Kerala: More than 2000 cases. Indian J Gastroenterol 2017;36:459-67. [PMID: 29368189 DOI: 10.1007/s12664-017-0809-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
66 Valmiki S, Ahuja V, Puri N, Paul J. miR-125b and miR-223 Contribute to Inflammation by Targeting the Key Molecules of NFκB Pathway. Front Med (Lausanne) 2019;6:313. [PMID: 32039213 DOI: 10.3389/fmed.2019.00313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
67 Sjöberg M, Magnuson A, Björk J, Benoni C, Almer S, Friis-Liby I, Hertervig E, Olsson M, Karlén P, Eriksson A. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377-387. [PMID: 23799948 DOI: 10.1111/apt.12387] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
68 Zhang Y, Chen D, Wang F, Li X, Xue X, Jiang M, Xu B, Chu Y, Wang W, Wu K, Mao R, Shen J, Yang S, Liang J. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif 2019;52:e12559. [PMID: 30659678 DOI: 10.1111/cpr.12559] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, Amanzada A. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One 2019;14:e0223893. [PMID: 31647834 DOI: 10.1371/journal.pone.0223893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
70 Ferrari L, Krane MK, Fichera A. Inflammatory bowel disease surgery in the biologic era. World J Gastrointest Surg 2016; 8(5): 363-370 [PMID: 27231514 DOI: 10.4240/wjgs.v8.i5.363] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
71 Estay C, Simian D, Lubascher J, Figueroa C, O’Brien A, Quera R. Ionizing radiation exposure in patients with inflammatory bowel disease: are we overexposing our patients? J Dig Dis. 2015;16:83-89. [PMID: 25420751 DOI: 10.1111/1751-2980.12213] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
72 Günaltay S, Repsilber D, Helenius G, Nyhlin N, Bohr J, Hultgren O, Hultgren Hörnquist E. Oligoclonal T-cell Receptor Repertoire in Colonic Biopsies of Patients with Microscopic Colitis and Ulcerative Colitis: . Inflammatory Bowel Diseases 2017;23:932-45. [DOI: 10.1097/mib.0000000000001127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R, Kagimoto S. Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. J Pediatr Gastroenterol Nutr 2017;64:955-61. [PMID: 27906804 DOI: 10.1097/MPG.0000000000001477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
74 Chaparro M, Gisbert JP. Maintenance therapy options for ulcerative colitis. Expert Opinion on Pharmacotherapy 2016;17:1339-49. [DOI: 10.1080/14656566.2016.1187132] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
75 Mak LY, Ng SC, Wong IOL, Li MKK, Lo FH, Wong MTL, Leung CM, Tsang SWC, Chan KH, Sze SF, Shan EHS, Lam BCY, Hui AJ, Hung IFN, Leung WK. Direct health-care cost utilization in Hong Kong inflammatory bowel disease patients in the initial 2 years following diagnosis. J Gastroenterol Hepatol 2018;33:141-9. [PMID: 28475813 DOI: 10.1111/jgh.13817] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
76 Damoiseaux J, Csernok E, Rasmussen N, Cohen Tervaert JW, Bossuyt X. Antineutrophil cytoplasmic antibodies: reporting and diagnostic strategies. Ann Rheum Dis 2017;76:e39. [PMID: 28274911 DOI: 10.1136/annrheumdis-2017-211171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
77 Burisch J, Vardi H, Pedersen N, Brinar M, Cukovic-cavka S, Kaimakliotis I, Duricova D, Bortlik M, Shonová O, Vind I, Avnstrøm S, Thorsgaard N, Krabbe S, Andersen V, Dahlerup JF, Kjeldsen J, Salupere R, Olsen J, Nielsen KR, Manninen P, Collin P, Katsanos KH, Tsianos EV, Ladefoged K, Lakatos L, Bailey Y, Oʼmorain C, Schwartz D, Lupinacci G, De Padova A, Jonaitis L, Kupcinskas L, Turcan S, Barros L, Magro F, Lazar D, Goldis A, Nikulina I, Belousova E, Fernandez A, Pineda JR, Almer S, Halfvarson J, Tsai H, Sebastian S, Friger M, Greenberg D, Lakatos PL, Langholz E, Odes S, Munkholm P. Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study. Inflammatory Bowel Diseases 2015;21:121-31. [DOI: 10.1097/mib.0000000000000250] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 5.6] [Reference Citation Analysis]
78 Sub Lee H, Jae Lee K. Immunoglobulin G4-related immune responses to common food antigens in patients with ulcerative colitis and Crohn's disease. Turk J Gastroenterol 2019;30:408–414. [PMID: 31060995 DOI: 10.5152/tjg.2019.18466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Okayasu M, Ogata H, Yoshiyama Y. Use of corticosteroids for remission induction therapy in patients with new-onset ulcerative colitis in real-world settings. J Mark Access Health Policy 2019;7:1565889. [PMID: 30719244 DOI: 10.1080/20016689.2019.1565889] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
80 Korolkova OY, Myers JN, Pellom ST, Wang L, M'Koma AE. Characterization of Serum Cytokine Profile in Predominantly Colonic Inflammatory Bowel Disease to Delineate Ulcerative and Crohn's Colitides. Clin Med Insights Gastroenterol. 2015;8:29-44. [PMID: 26078592 DOI: 10.4137/cgast.s20612] [Cited by in Crossref: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
81 Brégeon J, Coron E, Da Silva AC, Jaulin J, Aubert P, Chevalier J, Vergnolle N, Meurette G, Neunlist M. Sacral nerve stimulation enhances early intestinal mucosal repair following mucosal injury in a pig model. J Physiol 2016;594:4309-23. [PMID: 26939757 DOI: 10.1113/JP271783] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
82 Marinelli C, Zingone F, Inferrera M, Lorenzon G, Rigo A, Facchin S, Caccaro R, D'Incà R, Savarino EV. Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. J Dig Dis 2020;21:81-7. [PMID: 31859432 DOI: 10.1111/1751-2980.12837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
83 Lang-Schwarz C, Agaimy A, Atreya R, Becker C, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Tilg H, Villanacci V, Westerhoff M, Vieth M. Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Arch 2021;478:581-94. [PMID: 33373023 DOI: 10.1007/s00428-020-02982-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
84 Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Digestive and Liver Disease 2017;49:157-62. [DOI: 10.1016/j.dld.2016.10.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
85 García-López S, Bocos JM, Gisbert JP, Bajador E, Chaparro M, Castaño C, García-Erce JA, Gomollón F. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016;14:199-205. [PMID: 27177405 DOI: 10.2450/2016.0246-15] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
86 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Calabrese E, Monteleone G. Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab. JCM 2022;11:1679. [DOI: 10.3390/jcm11061679] [Reference Citation Analysis]
87 Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci 2015;60:3408-17. [PMID: 26386854 DOI: 10.1007/s10620-015-3868-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
88 Tursi A, Elisei W, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Mocci G, Penna A, Rodino' S, Sebkova L, de Medici A, Pranzo G, Ricciardelli C, Grasso G, Scorza S, Zampaletta C, Picchio M. Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers. Medicine (Baltimore) 2018;97:e11897. [PMID: 30142791 DOI: 10.1097/MD.0000000000011897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
89 Ma C, Huang V, Fedorak DK, Kroeker KI, Dieleman LA, Halloran BP, Fedorak RN. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. Journal of Crohn's and Colitis 2014;8:1454-63. [DOI: 10.1016/j.crohns.2014.05.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
90 Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J, Thörn M, Björk J, Hindorf U, Löfberg R, Bajor A, Hjortswang H, Hammarlund P, Grip O, Torp J, Marsal J, Hertervig E; Swedish Organization for the Study of Inflammatory Bowel diseases (SOIBD). Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Aliment Pharmacol Ther 2017;45:519-32. [PMID: 28025840 DOI: 10.1111/apt.13893] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
91 Shah A, Talley NJ, Koloski N, Macdonald GA, Kendall BJ, Shanahan ER, Walker MM, Keely S, Jones MP, Morrison M, Holtmann GJ. Duodenal bacterial load as determined by quantitative polymerase chain reaction in asymptomatic controls, functional gastrointestinal disorders and inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:155-67. [PMID: 32412673 DOI: 10.1111/apt.15786] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
92 Fornaro R, Caratto E, Caratto M, Sticchi C, Salerno A, Bianchi R, Scabini S, Casaccia M. Surgery of acute severe ulcerative colitis. Subtotal colectomy: when and how to do it? Eur Surg 2017;49:108-12. [DOI: 10.1007/s10353-016-0458-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
93 Gabryel M, Skrzypczak-Zielinska M, Kucharski MA, Slomski R, Dobrowolska A. The impact of genetic factors on response to glucocorticoids therapy in IBD. Scand J Gastroenterol 2016;51:654-65. [PMID: 26776488 DOI: 10.3109/00365521.2015.1132336] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
94 Gundersen MD, Goll R, Hol J, Olsen T, Rismo R, Sørbye SW, Sundnes O, Haraldsen G, Florholmen J. Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis. Sci Rep 2016;6:35403. [PMID: 27748438 DOI: 10.1038/srep35403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
95 Branchi F, Caprioli F, Orlando S, Conte D, Fraquelli M. Non-invasive evaluation of intestinal disorders: The role of elastographic techniques. World J Gastroenterol 2017; 23(16): 2832-2840 [PMID: 28522902 DOI: 10.3748/wjg.v23.i16.2832] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
96 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. Consenso mexicano para el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Revista de Gastroenterología de México 2018;83:144-67. [DOI: 10.1016/j.rgmx.2017.08.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
97 Bruno ME, Rogier EW, Arsenescu RI, Flomenhoft DR, Kurkjian CJ, Ellis GI, Kaetzel CS. Correlation of Biomarker Expression in Colonic Mucosa with Disease Phenotype in Crohn's Disease and Ulcerative Colitis. Dig Dis Sci. 2015;60:2976-2984. [PMID: 25956706 DOI: 10.1007/s10620-015-3700-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
98 Flores C, Francesconi CF, Meurer L. Quantitative assessment of CD30+ lymphocytes and eosinophils for the histopathological differential diagnosis of inflammatory bowel disease. J Crohns Colitis 2015;9:763-8. [PMID: 26048916 DOI: 10.1093/ecco-jcc/jjv097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
99 Dhingra R, Kedia S, Mouli VP, Garg SK, Singh N, Bopanna S, Singla V, Choudhury BN, Verma P, Tiwari V, Gupta SD, Makharia G, Ahuja V. Evaluating clinical, dietary, and psychological risk factors for relapse of ulcerative colitis in clinical, endoscopic, and histological remission: Predicting relapse in ulcerative colitis. Journal of Gastroenterology and Hepatology 2017;32:1698-705. [DOI: 10.1111/jgh.13770] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
100 Uzzan M, Cosnes J, Amiot A, Gornet J, Seksik P, Cotte E, Tiret E, Panis Y, Treton X. Long-term Follow-up After Ileorectal Anastomosis for Ulcerative Colitis: A GETAID/GETAID Chirurgie Multicenter Retrospective Cohort of 343 Patients. Annals of Surgery 2017;266:1029-34. [DOI: 10.1097/sla.0000000000002022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 2.8] [Reference Citation Analysis]
101 Calvet X, Panés J, Alfaro N, Hinojosa J, Sicilia B, Gallego M, Pérez I, Lázaro y de Mercado P, Gomollón F, Aldeguera X. Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis. 2014;8:240-251. [PMID: 24295646 DOI: 10.1016/j.crohns.2013.10.010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
102 Alexakis C, Saxena S, Chhaya V, Cecil E, Curcin V, Pollok R. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study. Inflamm Bowel Dis 2017;23:672-80. [PMID: 28151735 DOI: 10.1097/MIB.0000000000001031] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
103 Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, Valdivieso B, Correcher M, Aguas M. A Web-Based Telemanagement System for Improving Disease Activity and Quality of Life in Patients With Complex Inflammatory Bowel Disease: Pilot Randomized Controlled Trial. J Med Internet Res 2018;20:e11602. [PMID: 30482739 DOI: 10.2196/11602] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
104 Maillard MH, Bortolotti M, Vader J, Mottet C, Schoepfer A, Gonvers J, Burnand B, Froehlich F, Michetti P, Pittet V. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. Journal of Crohn's and Colitis 2014;8:825-34. [DOI: 10.1016/j.crohns.2013.12.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
105 Horjus Talabur Horje CS, Meijer J, Rovers L, van Lochem EG, Groenen MJ, Wahab PJ. Prevalence of Upper Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22:1896-1901. [PMID: 27057685 DOI: 10.1097/mib.0000000000000786] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
106 Brückner M, Heidemann J, Nowacki TM, Cordes F, Stypmann J, Lenz P, Gohar F, Lügering A, Bettenworth D. Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound. World J Gastroenterol 2017; 23(16): 2899-2911 [PMID: 28522908 DOI: 10.3748/wjg.v23.i16.2899] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
107 Armuzzi A, Biancone L, Daperno M, Coli A, Pugliese D, Annese V, Aratari A, Ardizzone S, Balestrieri P, Bossa F, Cappello M, Castiglione F, Cicala M, Danese S, D’incà R, Dulbecco P, Feliciangeli G, Fries W, Genise S, Gionchetti P, Gozzi S, Kohn A, Lorenzetti R, Milla M, Onali S, Orlando A, Papparella LG, Renna S, Ricci C, Rizzello F, Sostegni R, Guidi L, Papi C. Adalimumab in active ulcerative colitis: A “real-life” observational study. Digestive and Liver Disease 2013;45:738-43. [DOI: 10.1016/j.dld.2013.03.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
108 Park SK, Ye BD, Yang SK, Kim SO, Kim J, Kim JW, Park SH, Yang DH, Jung KW, Kim KJ, Byeon JS, Myung SJ, Kim JH. Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. J Crohns Colitis 2014;8:1254-60. [PMID: 24662395 DOI: 10.1016/j.crohns.2014.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
109 Freire P, Cardoso R, Figueiredo P, Donato MM, Ferreira M, Mendes S, Ferreira AM, Vasconcelos H, Portela F, Sofia C. NOD2 gene mutations in ulcerative colitis: useless or misunderstood? Int J Colorectal Dis. 2014;29:653-661. [PMID: 24651958 DOI: 10.1007/s00384-014-1850-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
110 To N, Ford AC, Gracie DJ. Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. Aliment Pharmacol Ther. 2016;44:117-126. [PMID: 27193202 DOI: 10.1111/apt.13663] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
111 Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T; INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol 2020;55:169-80. [PMID: 31529220 DOI: 10.1007/s00535-019-01625-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
112 Saito D, Matsuura M, Ozaki R, Tokunaga S, Minowa S, Mitsui T, Miura M, Sakuraba A, Hayashida M, Miyoshi J, Hisamatsu T. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021;5:1056-62. [PMID: 34584975 DOI: 10.1002/jgh3.12630] [Reference Citation Analysis]
113 Zidar N, Boštjančič E, Jerala M, Kojc N, Drobne D, Štabuc B, Glavač D. Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases - hallmark of epithelial-mesenchymal transition. J Cell Mol Med 2016;20:1813-20. [PMID: 27113480 DOI: 10.1111/jcmm.12869] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
114 Casellas F, Vicens DG, Menéndez SR, Oliver NA. Patients' perceptions, attitudes, and experiences about the management of mild-to-moderate ulcerative colitis. J Crohns Colitis 2014;8:1097-107. [DOI: 10.1016/j.crohns.2014.02.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
115 Peyrin-biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-farreras S, Fan T, Ding Q, Black CM, Kachroo S. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study. Digestive and Liver Disease 2016;48:601-7. [DOI: 10.1016/j.dld.2016.01.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
116 Trivedi PJ, Reece J, Laing RW, Slaney E, Cooney R, Gunson BK, Kamarajah SK, Pinkney T, Thompson F, Muiesan P, Schlegel A, Hirschfield GM, Iqbal T, Ferguson J. The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis. Aliment Pharmacol Ther 2018;48:322-32. [PMID: 29882252 DOI: 10.1111/apt.14828] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
117 Freire P, Figueiredo P, Cardoso R, Manuel Donato M, Ferreira M, Mendes S, Silva MR, Cipriano MA, Ferreira AM, Vasconcelos H, Portela F, Sofia C. Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis – a cross-sectional study. Scandinavian Journal of Gastroenterology 2014;49:1219-29. [DOI: 10.3109/00365521.2014.951390] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
119 Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337. [PMID: 23395397 DOI: 10.1016/j.crohns.2013.01.010] [Cited by in Crossref: 541] [Cited by in F6Publishing: 487] [Article Influence: 60.1] [Reference Citation Analysis]
120 Zollner-Schwetz I, Herzog KA, Feierl G, Leitner E, Schneditz G, Sprenger H, Prattes J, Petritsch W, Wenzl H, Kump P, Gorkiewicz G, Zechner E, Högenauer C. The Toxin-Producing Pathobiont Klebsiella oxytoca Is Not Associated with Flares of Inflammatory Bowel Diseases. Dig Dis Sci 2015;60:3393-8. [PMID: 26091802 DOI: 10.1007/s10620-015-3765-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
121 Xia H, Li S, He Y, Ren Q, Qin S. Long non-coding RNA ANRIL serves as a potential marker of disease risk, inflammation, and disease activity of pediatric inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101895] [Reference Citation Analysis]
122 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Reference Citation Analysis]
123 Carrasco A, Fernández-bañares F, Pedrosa E, Salas A, Loras C, Rosinach M, Aceituno M, Andújar X, Forné M, Zabana Y, Esteve M. Regional Specialisation of T Cell Subsets and Apoptosis in the Human Gut Mucosa: Differences Between Ileum and Colon in Healthy Intestine and Inflammatory Bowel Diseases. ECCOJC 2016;10:1042-54. [DOI: 10.1093/ecco-jcc/jjw066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
124 Fucilini LMP, Genaro LM, Sousa DCE, Coy CSR, Leal RF, Ayrizono MLS. EPIDEMIOLOGICAL PROFILE AND CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASES IN A BRAZILIAN REFERRAL CENTER. Arq Gastroenterol 2021;58:483-90. [PMID: 34909854 DOI: 10.1590/S0004-2803.202100000-87] [Reference Citation Analysis]
125 Nam K, Park SH, Oh JH, Lee HS, Noh S, Park JC, Kim JY, Oh EH, Kim J, Ham NS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK. Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. BMC Gastroenterol 2021;21:13. [PMID: 33407193 DOI: 10.1186/s12876-020-01597-1] [Reference Citation Analysis]
126 Taxonera C, Ponferrada Á, Riestra S, Bermejo F, Saro C, Martín-arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-arias F, Ferrer I, Marín-jiménez I, Hernández-camba A, Bastida G, Van Domselaar M, Martínez-montiel P, Olivares D, Rivero M, Fernandez-salazar L, Nantes Ó, Merino O, Alba C, Gisbert JP, del Mar Martín-rodriguez M, Botella B, Carpio D, Ceballos D, Verdejo C, Morales I, Legido J, Peñate M, Chaparro M, Algaba A, de Francisco R; CONVERT study group from GETECCU. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis 2018;12:1270-9. [DOI: 10.1093/ecco-jcc/jjy104] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
127 Protic M, Seibold F, Schoepfer A, Radojicic Z, Juillerat P, Bojic D, Mwinyi J, Mottet C, Jojic N, Beglinger C, Vavricka S, Rogler G, Frei P. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients. J Crohns Colitis 2014;8:1427-37. [PMID: 24908178 DOI: 10.1016/j.crohns.2014.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
128 Wang Y, Liu L, Guo Y, Mao T, Shi R, Li J. Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis. Exp Ther Med 2017;14:1327-36. [PMID: 28781623 DOI: 10.3892/etm.2017.4701] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
129 Prager M, Büttner J, Grunert P, Ellinghaus D, Büning C. A Promoter Variant Within the Aryl Hydrocarbon Receptor Gene Is Associated with an Epithelial Barrier Defect in Smokers with Crohn's Disease. Inflamm Bowel Dis 2016;22:2356-68. [PMID: 27598741 DOI: 10.1097/MIB.0000000000000910] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
130 Le Baut G, Kirchgesner J, Amiot A, Lefevre JH, Chafai N, Landman C, Nion I, Bourrier A, Delattre C, Martineau C, Sokol H, Seksik P, Nguyen Y, Marion Y, Lebreton G, Carbonnel F, Viennot S, Beaugerie L; Saint Antoine IBD Network. A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1602-1610.e1. [PMID: 31927106 DOI: 10.1016/j.cgh.2019.12.036] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
131 Serrano-montalbán B, Arias Á, Friginal-ruiz AB, Lucendo AJ. The Use of the Fracture Risk Assessment (FRAX®) Tool in Predicting Risk of Fractures in Patients With Inflammatory Bowel Disease: A Systematic Review. Journal of Clinical Densitometry 2017;20:180-7. [DOI: 10.1016/j.jocd.2016.08.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
132 Tan CX, Brand HS, de Boer NK, Forouzanfar T. Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis. Br Dent J. 2017;222:53-57. [PMID: 28084352 DOI: 10.1038/sj.bdj.2017.37] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
133 Cai X, Wang X, He M, Wang Y, Lan M, Zhao Y, Gao F. Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy. Int J Pharm 2021;606:120836. [PMID: 34217824 DOI: 10.1016/j.ijpharm.2021.120836] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Rai T, Choudhury BN, Kedia S, Bopanna S, Venigalla PM, Garg SK, Singla V, Makharia G, Ahuja V. Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. Dig Dis Sci. 2017;62:1025-1034. [PMID: 28161855 DOI: 10.1007/s10620-017-4450-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
135 Trigo-vicente C, Gimeno-ballester V, García-lópez S, López-del Val A. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm 2018;40:1411-9. [DOI: 10.1007/s11096-018-0743-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
136 Muñoz Villafranca C, Bravo Rodríguez MT, Ortiz de Zárate J, Arreba González P, García Kamiruaga I, Heras Martín JI, Cabezudo Gil P, Orive Cura V. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission]. Gastroenterol Hepatol 2016;39:442-8. [PMID: 26948837 DOI: 10.1016/j.gastrohep.2015.11.011] [Reference Citation Analysis]
137 Nissen LHC, Pierik M, Derikx LAAP, de Jong E, Kievit W, van den Heuvel TRA, van Rosendael AR, Plasmeijer EI, Dewint P, Verhoeven RHA, Overbeek LIH, Nagtegaal ID, Hoentjen F, van der Meulen–de Jong AE. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma: . Inflammatory Bowel Diseases 2017;23:2018-26. [DOI: 10.1097/mib.0000000000001191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
138 Prager M, Buettner J, Buening C. Genes involved in the regulation of intestinal permeability and their role in ulcerative colitis. J Dig Dis. 2015;16:713-722. [PMID: 26512799 DOI: 10.1111/1751-2980.12296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
139 Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R, Geboes K; European Society of Pathology; European Crohn's and Colitis Foundation. The histopathological approach to inflammatory bowel disease: a practice guide. Virchows Arch. 2014;464:511-527. [PMID: 24487791 DOI: 10.1007/s00428-014-1543-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
140 Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, Dash NR, Pal S, Makharia G, Ahuja V. Left-sided colitis and extensive colitis have similar colectomy rates after index episode of acute severe colitis: A long-term follow-up study: Disease extent and acute severe colitis. JGH Open 2017;1:134-9. [DOI: 10.1002/jgh3.12023] [Reference Citation Analysis]
141 Kirov S, Sasson A, Zhang C, Chasalow S, Dongre A, Steen H, Stensballe A, Andersen V, Birkelund S, Bennike TB. Degradation of the extracellular matrix is part of the pathology of ulcerative colitis. Mol Omics 2019;15:67-76. [PMID: 30702115 DOI: 10.1039/c8mo00239h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
142 Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ. Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin. Therap Adv Gastroenterol. 2018;11:1756283X17744739. [PMID: 29383026 DOI: 10.1177/1756283x17744739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
143 Nazareth N, Magro F, Machado E, Ribeiro TG, Martinho A, Rodrigues P, Alves R, Macedo GN, Gracio D, Coelho R, Abreu C, Appelberg R, Dias C, Macedo G, Bull T, Sarmento A. Prevalence of Mycobacterium avium subsp. paratuberculosis and Escherichia coli in blood samples from patients with inflammatory bowel disease. Med Microbiol Immunol 2015;204:681-92. [PMID: 25994082 DOI: 10.1007/s00430-015-0420-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
144 Grimstad T, Norheim KB, Isaksen K, Leitao K, Hetta AK, Carlsen A, Karlsen LN, Skoie IM, Gøransson L, Harboe E, Aabakken L, Omdal R. Fatigue in Newly Diagnosed Inflammatory Bowel Disease. J Crohns Colitis 2015;9:725-30. [PMID: 25994356 DOI: 10.1093/ecco-jcc/jjv091] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
145 Saito H, Hirayama A, Umemura T, Joshita S, Mukawa K, Suga T, Tanaka E, Ota M. Association between KIR-HLA combination and ulcerative colitis and Crohn's disease in a Japanese population. PLoS One 2018;13:e0195778. [PMID: 29649328 DOI: 10.1371/journal.pone.0195778] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
146 Campos S, Portela F, Sousa P, Sofia C. Inflammatory bowel disease: adherence to immunomodulators in a biological therapy era. Eur J Gastroenterol Hepatol 2016;28:1313-9. [PMID: 27501126 DOI: 10.1097/MEG.0000000000000704] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
147 De Sloovere MMW, De Smet D, Baert FJ, Debrabandere J, Vanpoucke HJM. Analytical and diagnostic performance of two automated fecal calprotectin immunoassays for detection of inflammatory bowel disease. Clin Chem Lab Med 2017;55:1435-46. [PMID: 28076305 DOI: 10.1515/cclm-2016-0796] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
148 Aguas M, Del Hoyo J, Faubel R, Muñoz D, Domínguez D, Bastida G, Navarro B, Barrios A, Valdivieso B, Correcher M, Nos P. A Web-Based Telemanagement System for Patients With Complex Inflammatory Bowel Disease: Protocol for a Randomized Controlled Clinical Trial. JMIR Res Protoc 2018;7:e190. [PMID: 30578197 DOI: 10.2196/resprot.9639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
149 Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D’incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V, Saettone S, Tari R, Petruzzellis C, Meucci G, Imperiali G, Guglielmi FW, Mazzuoli S, Caserta L, Caterina Parodi M, Colli A, Ronchetti A, Pugliese D, Geccherle A, Rogai F, Milani S, Renna S, Cassinotti A, Andriulli A, Martino G, Scrivo B, Troncone E, Kohn A, Bertani L, Lorenzon G, Ghione S, Nardone O, Vecchi M, Bertani A, Bosani MA, Bezzio C, Salerno R; PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases 2019;25:568-79. [DOI: 10.1093/ibd/izy264] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
150 Ciccacci C, Politi C, Biancone L, Latini A, Novelli G, Calabrese E, Borgiani P. Polymorphisms in MIR122, MIR196A2, and MIR124A Genes are Associated with Clinical Phenotypes in Inflammatory Bowel Diseases. Mol Diagn Ther. 2017;21:107-114. [PMID: 27718165 DOI: 10.1007/s40291-016-0240-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
151 Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis 2020;14:1274-81. [PMID: 32179906 DOI: 10.1093/ecco-jcc/jjaa041] [Reference Citation Analysis]
152 Ciccocioppo R, Racca F, Paolucci S, Campanini G, Pozzi L, Betti E, Riboni R, Vanoli A, Baldanti F, Corazza GR. Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: Need for mucosal viral load measurement. World J Gastroenterol 2015; 21(6): 1915-1926 [PMID: 25684960 DOI: 10.3748/wjg.v21.i6.1915] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
153 Lobatón T, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther 2015;42:441-51. [PMID: 26104047 DOI: 10.1111/apt.13294] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 12.9] [Reference Citation Analysis]
154 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
155 Van Gossum A. Wireless capsule endoscopy of the large intestine: a review with future projections. Curr Opin Gastroenterol. 2014;30:472-476. [PMID: 25010682 DOI: 10.1097/mog.0000000000000103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Gokcan H, Yurtcu E, Selcuk H, Sahin FI. Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis. Bosn J Basic Med Sci 2015;15:73-7. [PMID: 26042517 DOI: 10.17305/bjbms.2015.387] [Reference Citation Analysis]
157 Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB, Hart AL, Hindryckx P. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11:649-670. [PMID: 28158501 DOI: 10.1093/ecco-jcc/jjx008] [Cited by in Crossref: 682] [Cited by in F6Publishing: 563] [Article Influence: 170.5] [Reference Citation Analysis]
158 Kim ES. Role of Advanced Endoscopic Imaging Techniques in the Management of Inflammatory Bowel Disease. Clin Endosc 2017;50:424-8. [PMID: 29017290 DOI: 10.5946/ce.2017.143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
159 Woo DH, Kim KO, Kang MK, Lee SH, Jang BI, Kim TN. Predictors and clinical outcomes of follow-up loss in patients with inflammatory bowel disease. J Gastroenterol Hepatol 2018;33:1834-8. [PMID: 29664147 DOI: 10.1111/jgh.14258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
160 Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. World J Microbiol Biotechnol 2019;35:45. [PMID: 30810891 DOI: 10.1007/s11274-019-2615-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
161 Golovics PA, Mandel MD, Lovasz BD, Lakatos PL. Inflammatory bowel disease course in Crohn’s disease: Is the natural history changing? World J Gastroenterol 2014; 20(12): 3198-3207 [PMID: 24696605 DOI: 10.3748/wjg.v20.i12.3198] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
162 Shen Z, Zheng K, Zou J, Gu P, Xing J, Zhang L, Zhu L, Shen H. Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial. Trials 2021;22:55. [PMID: 33441157 DOI: 10.1186/s13063-020-05012-8] [Reference Citation Analysis]
163 Bahreyni A, Samani SS, Khazaei M, Ryzhikov M, Avan A, Hassanian SM. Therapeutic potentials of adenosine receptors agonists and antagonists in colitis; Current status and perspectives. J Cell Physiol 2018;233:2733-40. [DOI: 10.1002/jcp.26073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
164 Lopez-sanroman A. The Concept of Mucosal Healing in Ulcerative Colitis: Time and Reasons for a Reappraisal. ECCOJC 2015;10:3-4. [DOI: 10.1093/ecco-jcc/jjv183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
165 Ellul P, Zammita SC, Katsanos KH, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno SC, Kopylov U, Fiorino G. Perception of Reproductive Health in Women with Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:886-891. [PMID: 26783343 DOI: 10.1093/ecco-jcc/jjw011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
166 Goyal S, Rampal R, Kedia S, Mahajan S, Bopanna S, Yadav DP, Jain S, Singh AK, Wari MN, Makharia G, Awasthi A, Ahuja V. Urinary potassium is a potential biomarker of disease activity in Ulcerative colitis and displays in vitro immunotolerant role. Sci Rep 2017;7:18068. [PMID: 29273710 DOI: 10.1038/s41598-017-18046-x] [Reference Citation Analysis]
167 Chen J, Andrews JM, Kariyawasam V, Moran N, Gounder P, Collins G, Walsh AJ, Connor S, Lee TWT, Koh CE, Chang J, Paramsothy S, Tattersall S, Lemberg DA, Radford-smith G, Lawrance IC, Mclachlan A, Moore GT, Corte C, Katelaris P, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther 2016;44:127-44. [DOI: 10.1111/apt.13670] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
168 Peyrin-biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel J, Hanauer SB, Rycroft B. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clinical Gastroenterology and Hepatology 2016;14:348-354.e17. [DOI: 10.1016/j.cgh.2015.06.001] [Cited by in Crossref: 186] [Cited by in F6Publishing: 169] [Article Influence: 31.0] [Reference Citation Analysis]
169 Walsh AJ, Ghosh A, Brain AO, Buchel O, Burger D, Thomas S, White L, Collins GS, Keshav S, Travis SP. Comparing disease activity indices in ulcerative colitis. J Crohns Colitis. 2014;8:318-325. [PMID: 24120021 DOI: 10.1016/j.crohns.2013.09.010] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
170 Bálint A, Rutka M, Végh Z, Kürti Z, Gecse KB, Banai J, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Patai Á, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Bor R, Milassin Á, Fábián A, Nagy F, Kolar M, Bortlik M, Duricova D, Hruba V, Lukas M, Mitrova K, Malickova K, Lukas M, Lakatos PL, Molnár T, Farkas K. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opinion on Drug Safety 2017;16:885-90. [DOI: 10.1080/14740338.2017.1323330] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
171 Kampa KC, Morsoletto DBG, Loures MR, Pissaia A, Nones RB, Ivantes CAP. IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT. Arq Gastroenterol 2017;54:333-7. [PMID: 28954041 DOI: 10.1590/S0004-2803.201700000-41] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.6] [Reference Citation Analysis]
172 Kim KO, Chiorean MV. Advanced neoplasia detection using chromoendoscopy and white light colonoscopy for surveillance in patients with inflammatory bowel disease. Intest Res 2020;18:438-46. [PMID: 33131232 DOI: 10.5217/ir.2019.00090] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
173 Dart RJ, Samaan MA, Powell N, Irving PM. Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis. Clin Exp Gastroenterol 2017;10:57-66. [PMID: 28424557 DOI: 10.2147/CEG.S110547] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
174 Eronen H, Ilus T, Jussila A, Huhtala H, Collin P, Oksanen P. Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids. Scand J Gastroenterol 2021;56:234-8. [PMID: 33496198 DOI: 10.1080/00365521.2020.1867892] [Reference Citation Analysis]
175 Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory Bowel Disease. Dtsch Arztebl Int 2016;113:72-82. [PMID: 26900160 DOI: 10.3238/arztebl.2016.0072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
176 Eronen H, Kolehmainen S, Koffert J, Koskinen I, Oksanen P, Jussila A, Huhtala H, Sipponen T, Ilus T. Combining biological therapies in patients with inflammatory bowel disease: a Finnish multi-centre study. Scand J Gastroenterol 2022;:1-6. [PMID: 35238727 DOI: 10.1080/00365521.2022.2045350] [Reference Citation Analysis]
177 Tanaka M, Kawakami A, Maeda S, Kunisaki R, Morisky DE. Validity and Reliability of the Japanese Version of the Morisky Medication Adherence Scale-8 in Patients With Ulcerative Colitis. Gastroenterol Nurs 2021;44:31-8. [PMID: 33351521 DOI: 10.1097/SGA.0000000000000533] [Reference Citation Analysis]
178 Argyriou K, Roma E, Kapsoritakis A, Tsakiridou E, Oikonomou K, Manolakis A, Potamianos S. The Rating Form of IBD Patient Concerns: Translation, Validation, and First Implementation of the Greek Version. Gastroenterol Res Pract 2017;2017:6267175. [PMID: 28529522 DOI: 10.1155/2017/6267175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
179 Chavarría C, Casanova MJ, Chaparro M, Barreiro-de Acosta M, Ezquiaga E, Bujanda L, Rivero M, Argüelles-Arias F, Martín-Arranz MD, Martínez-Montiel MP, Valls M, Ferreiro-Iglesias R, Llaó J, Moraleja-Yudego I, Casellas F, Antolín-Melero B, Cortés X, Plaza R, Pineda JR, Navarro-Llavat M, García-López S, Robledo-Andrés P, Marín-Jiménez I, García-Sánchez V, Merino O, Algaba A, Arribas-López MR, Banales JM, Castro B, Castro-Laria L, Honrubia R, Almela P, Gisbert JP. Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. J Crohns Colitis 2019;13:996-1002. [PMID: 30721954 DOI: 10.1093/ecco-jcc/jjz024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
180 Rampal R, Wari N, Singh AK, Das U, Bopanna S, Gupta V, Nayak B, Velapandian T, Kedia S, Kumar D, Awasthi A, Ahuja V. Retinoic Acid Is Elevated in the Mucosa of Patients With Active Ulcerative Colitis and Displays a Proinflammatory Role by Augmenting IL-17 and IFNγ Production. Inflamm Bowel Dis 2021;27:74-83. [PMID: 32469071 DOI: 10.1093/ibd/izaa121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
181 Kim JH, Cheon JH, Park Y, Lee HJ, Park SJ, Kim TI, Kim WH. Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. Scand J Gastroenterol 2016;51:1069-74. [PMID: 26895215 DOI: 10.3109/00365521.2016.1150503] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
182 Nguyen VQ, Jiang D, Hoffman SN, Guntaka S, Mays JL, Wang A, Gomes J, Sorrentino D. Impact of Diagnostic Delay and Associated Factors on Clinical Outcomes in a U.S. Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2017;23:1825-1831. [PMID: 28885229 DOI: 10.1097/mib.0000000000001257] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
183 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
184 Wang X, Jiang Y, Zhu Y, Zhang M, Li M, Wang H, Gao P. Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis. J Cell Mol Med 2016;20:804-14. [PMID: 26800315 DOI: 10.1111/jcmm.12728] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
185 Qin W, Li L, Wang T, Huang H, Gao Y. Urine Proteome Changes in a TNBS‐Induced Colitis Rat Model. Prot Clin Appl 2019;13:1800100. [DOI: 10.1002/prca.201800100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
186 Mohammadi-moghadam F, Karami Horestani M, Nourmoradi H, Heidari M, Sadeghi M, Ahmadi A, Fadaei A, Hemati S, Bagherzadeh F. Toxic and essential elements in drinking water, blood, hair and intestinal tissues of ulcerative colitis patients: probabilistic health risk assessment for drinking water consumers. Toxin Reviews. [DOI: 10.1080/15569543.2021.1895840] [Reference Citation Analysis]
187 Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, Ferrante M, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. Inflamm Bowel Dis 2017;23:1605-13. [PMID: 28590343 DOI: 10.1097/MIB.0000000000001160] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
188 Mocciaro F, Pecoraro GM, Di Mitri R, Scimeca D, Bossa F, Russo G, Martino G, Costanza V, Profita MA, Orlando C, Profeta G, Tinè F. Nurse in patients’ health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores. Digestive and Liver Disease 2017;49:1110-4. [DOI: 10.1016/j.dld.2017.06.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
189 Golik M, Kurek M, Poteralska A, Bieniek E, Marynka A, Pabich G, Liebert A, Kłopocka M, Rydzewska G. Working Group Guidelines on the nursing roles in caring for patients with Crohn's disease and ulcerative colitis in Poland. Prz Gastroenterol 2014;9:179-93. [PMID: 25276248 DOI: 10.5114/pg.2014.45098] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
190 Amara J, Saliba Y, Hajal J, Smayra V, Bakhos JJ, Sayegh R, Fares N. Circadian Rhythm Disruption Aggravates DSS-Induced Colitis in Mice with Fecal Calprotectin as a Marker of Colitis Severity. Dig Dis Sci 2019;64:3122-33. [PMID: 31115725 DOI: 10.1007/s10620-019-05675-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
191 Ouryemchi M, Jabi R, Soussan H, Najioui Y, Bouziane M. Degenerative Ulcerative Colitis After One Year of Evolution in a 20-Year-Old Patient. Cureus 2021;13:e18582. [PMID: 34760425 DOI: 10.7759/cureus.18582] [Reference Citation Analysis]
192 Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J. Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. J Crohns Colitis 2017;11:1317-25. [PMID: 28981846 DOI: 10.1093/ecco-jcc/jjx093] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
193 Di Girolamo M, Sartini A, Critelli R, Bertani A, Merighi A, Villa E. Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study. Ther Apher Dial 2016;20:668-76. [PMID: 27921374 DOI: 10.1111/1744-9987.12453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
194 Smids C, Horjus Talabur Horje CS, Drylewicz J, Roosenboom B, Groenen MJM, van Koolwijk E, van Lochem EG, Wahab PJ. Intestinal T Cell Profiling in Inflammatory Bowel Disease: Linking T Cell Subsets to Disease Activity and Disease Course. J Crohns Colitis. 2018;12:465-475. [PMID: 29211912 DOI: 10.1093/ecco-jcc/jjx160] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
195 Zhong C, Cheng X, Jia B, Xiong P, Lu J, Zhang P, Liu X, Chen Y. Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23038. [PMID: 33217804 DOI: 10.1097/MD.0000000000023038] [Reference Citation Analysis]
196 Cui DJ, Chen H, Hu M. Letter: anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 for ulcerative colitis. Aliment Pharmacol Ther 2016;44:767. [PMID: 27593425 DOI: 10.1111/apt.13735] [Reference Citation Analysis]
197 Liefferinckx C, Franchimont D. Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2018;24:1428-39. [PMID: 29788122 DOI: 10.1093/ibd/izy109] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
198 Jia Y, Li C, Yang X, Dong Z, Huang K, Luo Y, Li X, Sun C, Feng ST, Li ZP. CT Enterography score: a potential predictor for severity assessment of active ulcerative colitis. BMC Gastroenterol. 2018;18:173. [PMID: 30413186 DOI: 10.1186/s12876-018-0890-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
199 Irani NR, Wang LM, Collins GS, Keshav S, Travis SPL. Correlation Between Endoscopic and Histological Activity in Ulcerative Colitis Using Validated Indices. Journal of Crohn's and Colitis 2018;12:1151-7. [DOI: 10.1093/ecco-jcc/jjy081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
200 Morilla I, Uzzan M, Laharie D, Cazals-Hatem D, Denost Q, Daniel F, Belleannee G, Bouhnik Y, Wainrib G, Panis Y, Ogier-Denis E, Treton X. Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019;17:905-913. [PMID: 30223112 DOI: 10.1016/j.cgh.2018.08.068] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
201 Kump P, Wurm P, Gröchenig HP, Wenzl H, Petritsch W, Halwachs B, Wagner M, Stadlbauer V, Eherer A, Hoffmann KM, Deutschmann A, Reicht G, Reiter L, Slawitsch P, Gorkiewicz G, Högenauer C. The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis. Aliment Pharmacol Ther 2018;47:67-77. [PMID: 29052237 DOI: 10.1111/apt.14387] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
202 Kamat N, Rajan Mallayasamy S, Sharma PSVN, Kamath A, Pai CG. Video assisted patient education improves compliance with follow up and depression scores in Inflammatory Bowel Diseases. Postgrad Med 2018;130:355-60. [PMID: 29460659 DOI: 10.1080/00325481.2018.1442978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
203 Biancone L, Armuzzi A, Scribano ML, D’inca R, Castiglione F, Papi C, Angelucci E, Daperno M, Mocciaro F, Riegler G, Fries W, Meucci G, Alvisi P, Spina L, Ardizzone S, Petruzziello C, Ruffa A, Kohn A, Vecchi M, Guidi L, Di Mitri R, Renna S, Emma C, Rogai F, Rossi A, Orlando A, Pallone F; on behalf of the Italian Group for the study of Inflammatory Bowel Disease. Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. ECCOJC 2016;10:913-24. [DOI: 10.1093/ecco-jcc/jjw048] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
204 Ponsioen CY, Chapman RW, Chazouillères O, Hirschfield GM, Karlsen TH, Lohse AW, Pinzani M, Schrumpf E, Trauner M, Gores GJ. Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. Hepatology 2016;63:1357-67. [PMID: 26418478 DOI: 10.1002/hep.28256] [Cited by in Crossref: 94] [Cited by in F6Publishing: 80] [Article Influence: 13.4] [Reference Citation Analysis]
205 Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol 2017;12:169-74. [PMID: 29123576 DOI: 10.5114/pg.2017.70468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
206 Taxonera C, Ponferrada Á, Bermejo F, Riestra S, Saro C, Martín-Arranz MD, Cabriada JL, Barreiro-de Acosta M, de Castro ML, López-Serrano P, Barrio J, Suarez C, Iglesias E, Argüelles-Arias F, Ferrer I, Marín-Jiménez I, Hernández-Camba A, Bastida G, Van Domselaar M, Martínez-Montiel P, Olivares D, Alba C, Gisbert JP; SEGURTB study group from GETECCU. Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. J Crohns Colitis 2017;11:792-800. [PMID: 28333182 DOI: 10.1093/ecco-jcc/jjx022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
207 Rinawi F, Assa A, Eliakim R, Mozer-glassberg Y, Nachmias-friedler V, Niv Y, Rosenbach Y, Silbermintz A, Zevit N, Shamir R. Risk of Colectomy in Patients With Pediatric-onset Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2017;65:410-5. [DOI: 10.1097/mpg.0000000000001545] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 3.2] [Reference Citation Analysis]
208 Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis 2018;12:1021-9. [PMID: 29767728 DOI: 10.1093/ecco-jcc/jjy049] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
209 Xiao N, Liu F, Zhou G, Sun M, Ai F, Liu Z. Food-specific IgGs Are Highly Increased in the Sera of Patients with Inflammatory Bowel Disease and Are Clinically Relevant to the Pathogenesis. Intern Med 2018;57:2787-98. [PMID: 29780153 DOI: 10.2169/internalmedicine.9377-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
210 Cañas-Ventura A, Márquez L, Ricart E, Domènech E, Gisbert JP, García-Sanchez V, Marín-Jiménez I, Rodriguez-Moranta F, Gomollón F, Calvet X, Merino O, Garcia-Planella E, Vázquez-Romero N, Esteve M, Iborra M, Gutiérrez A, Vera M, Andreu M; Spanish GETECCU group (ENEIDA project). Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis 2014;8:1287-93. [PMID: 24726696 DOI: 10.1016/j.crohns.2014.03.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
211 Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, Mulcahy HE, Cullen G, Doherty GA. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-335. e1. [PMID: 25086187 DOI: 10.1016/j.cgh.2014.07.041] [Cited by in Crossref: 152] [Cited by in F6Publishing: 134] [Article Influence: 19.0] [Reference Citation Analysis]
212 Chen J, Chen X, Sun Y, Xie Y, Wang X, Li R, Hesketh T. The physiological and psychological effects of cognitive behavior therapy on patients with inflammatory bowel disease before COVID-19: a systematic review. BMC Gastroenterol 2021;21:469. [PMID: 34911469 DOI: 10.1186/s12876-021-02003-0] [Reference Citation Analysis]
213 Lin L, Wang T, Lu Y, Chen P, Zhang Y, Zu X, Chen B, Mao R, Feng R, Cui Y, Zhang S, He Y. Mucosal healing and quality of life in therapeutic goals of ulcerative colitis: occurrence and related factors of functional bowel disorder-like symptoms. Therap Adv Gastroenterol 2022;15:175628482210925. [DOI: 10.1177/17562848221092597] [Reference Citation Analysis]
214 Despalatović BR, Babić M, Bratanić A, Tonkić A, Vilović K. Difference in Presence and Number of CD83+ Dendritic Cells in Patients with Ulcerative Colitis and Crohn's Disease. Sci Rep 2020;10:10055. [PMID: 32572123 DOI: 10.1038/s41598-020-67149-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
215 Bennike TB, Carlsen TG, Ellingsen T, Bonderup OK, Glerup H, Bøgsted M, Christiansen G, Birkelund S, Stensballe A, Andersen V. Neutrophil Extracellular Traps in Ulcerative Colitis: A Proteome Analysis of Intestinal Biopsies. Inflamm Bowel Dis. 2015;21:2052-2067. [PMID: 25993694 DOI: 10.1097/mib.0000000000000460] [Cited by in Crossref: 74] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
216 Dignass A, Akbar A, Hart A, Subramanian S, Bommelaer G, Baumgart DC, Grimaud JC, Cadiot G, Makins R, Hoque S, Bouguen G, Bonaz B. Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis. 2016;10:812-820. [PMID: 26818659 DOI: 10.1093/ecco-jcc/jjw032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
217 Schneider A, Hirth M, Weiss C, Weidner P, Antoni C, Thomann A, Reindl W, Ebert MP, Pfützer RH. Prevalence of inflammatory bowel disease in alcoholic, non-alcoholic and autoimmune pancreatitis. Z Gastroenterol 2018;56:469-78. [PMID: 29734447 DOI: 10.1055/s-0043-123881] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Testa A, Rispo A, Romano M, Riegler G, Selvaggi F, Bottiglieri E, Martorano M, Rea M, Gravina A, Nardone OM. The burden of anaemia in patients with inflammatory bowel diseases. Dig Liver Dis. 2016;48:267-270. [PMID: 26698411 DOI: 10.1016/j.dld.2015.10.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
219 Li MY, Zhang ZH, Wang Z, Zuo HX, Wang JY, Xing Y, Jin CH, Xu GH, Piao LX, Ma J, Jin X. Convallatoxin protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB signaling through activation of PPARγ. Pharmacological Research 2019;147:104355. [DOI: 10.1016/j.phrs.2019.104355] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
220 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 92] [Cited by in F6Publishing: 75] [Article Influence: 30.7] [Reference Citation Analysis]
221 Zamani S, Zali MR, Aghdaei HA, Sechi LA, Niegowska M, Caggiu E, Keshavarz R, Mosavari N, Feizabadi MM. Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients. Gut Pathog 2017;9:1. [PMID: 28053669 DOI: 10.1186/s13099-016-0151-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
222 Gallo G, Kotze PG, Spinelli A. Surgery in ulcerative colitis: When? How? Best Practice & Research Clinical Gastroenterology 2018;32-33:71-8. [DOI: 10.1016/j.bpg.2018.05.017] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
223 Fischer S, Neurath MF, Atreya R. [Colitis ulcerosa - a diagnostic and therapeutic update]. MMW Fortschr Med 2016;158:77-80. [PMID: 27116171 DOI: 10.1007/s15006-016-8152-x] [Reference Citation Analysis]
224 Rizzo G, Pugliese D, Armuzzi A, Coco C. Anti-TNF alpha in the treatment of ulcerative colitis: A valid approach for organ-sparing or an expensive option to delay surgery? World J Gastroenterol 2014; 20(17): 4839-4845 [PMID: 24803795 DOI: 10.3748/wjg.v20.i17.4839] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
225 Rieder F, Kurada S, Grove D, Cikach F, Lopez R, Patel N, Singh A, Alkhouri N, Shen B, Brzezinski A, Baker M, Fiocchi C, Dweik RA. A Distinct Colon-Derived Breath Metabolome is Associated with Inflammatory Bowel Disease, but not its Complications. Clin Transl Gastroenterol 2016;7:e201. [PMID: 27831543 DOI: 10.1038/ctg.2016.57] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
226 Vogel H, Halpert D, Horoupian DS. Hypoplasia of posterior spinal roots and dorsal spinal tracts with arthrogryposis multiplex congenita. Acta Neuropathol. 1990;79:692-696. [PMID: 2360413 DOI: 10.1136/gutjnl-2013-304636] [Cited by in Crossref: 221] [Cited by in F6Publishing: 196] [Article Influence: 6.9] [Reference Citation Analysis]
227 Xie T, Zhao C, Ding C, Zhang T, Dai X, Lv T, Li Y, Guo Z, Gong J, Zhu W. Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study. Dig Liver Dis. 2017;49:984-990. [PMID: 28539226 DOI: 10.1016/j.dld.2017.04.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
228 Uzzan M, Galicier L, Gornet JM, Oksenhendler E, Fieschi C, Allez M, Bouhnik Y, Kirchgesner J, Boutboul D, Treton X, Gérard L, Mahévas M, Cosnes J, Amiot A. Autoimmune cytopenias associated with inflammatory bowel diseases: Insights from a multicenter retrospective cohort. Dig Liver Dis 2017;49:397-404. [PMID: 28063954 DOI: 10.1016/j.dld.2016.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
229 Kovacs G, Sipeki N, Suga B, Tornai T, Fechner K, Norman GL, Shums Z, Antal-Szalmas P, Papp M. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS One 2018;13:e0194166. [PMID: 29590158 DOI: 10.1371/journal.pone.0194166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
230 Hirayama Y, Ando T, Hirooka Y, Watanabe O, Miyahara R, Nakamura M, Yamamura T, Goto H. Characteristic endoscopic findings and risk factors for cytomegalovirus-associated colitis in patients with active ulcerative colitis. World J Gastrointest Endosc 2016; 8(6): 301-309 [PMID: 27014426 DOI: 10.4253/wjge.v8.i6.301] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
231 Dogan S, Guven K, Celikbilek M, Deniz K, Saraymen B, Gursoy S. Serum Visfatin Levels in Ulcerative Colitis. J Clin Lab Anal 2016;30:552-6. [PMID: 26668098 DOI: 10.1002/jcla.21901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
232 Pellino G, Sciaudone G, Caserta V, Candilio G, De Fatico GS, Gagliardi S, Landino I, Patturelli M, Riegler G, Di Caprio EL, Canonico S, Gritti P, Selvaggi F. Fatigue in inflammatory bowel diseases: Relationship with age and disease activity. International Journal of Surgery 2014;12:S60-3. [DOI: 10.1016/j.ijsu.2014.08.379] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
233 Kevans D, Kirsch R, Dargavel C, Kabakchiev B, Riddell R, Silverberg MS. Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis. Inflamm Bowel Dis. 2020;26:1722-1729. [PMID: 31883337 DOI: 10.1093/ibd/izz308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
234 Connolly MP, Kuyvenhoven JP, Postma MJ, Nielsen SK. Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4g or twice-daily 2g mesalazine dosing. Journal of Crohn's and Colitis 2014;8:357-62. [DOI: 10.1016/j.crohns.2013.09.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
235 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 297] [Article Influence: 120.3] [Reference Citation Analysis]
236 Sood R, Ansari S, Clark T, Hamlin PJ, Ford AC. Long-term efficacy and safety of azathioprine in ulcerative colitis. J Crohns Colitis 2015;9:191-7. [PMID: 25518053 DOI: 10.1093/ecco-jcc/jju010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
237 Lee HS, Yang SK, Soh JS, Lee S, Bae JH, Lee HJ, Park SH, Yang DH, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH. Short- and Long-Term Outcomes of Acute Severe Ulcerative Colitis in Korea: The 1999-2005 Cohort. Inflamm Bowel Dis 2015;21:1825-31. [PMID: 25985248 DOI: 10.1097/MIB.0000000000000447] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
238 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
239 Bots S, Nylund K, Löwenberg M, Gecse K, D'Haens G. Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index. J Crohns Colitis 2021;15:1264-71. [PMID: 33411887 DOI: 10.1093/ecco-jcc/jjab002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
240 Inokuchi T, Kato J, Hiraoka S, Suzuki H, Nakarai A, Hirakawa T, Akita M, Takahashi S, Harada K, Okada H, Yamamoto K. Long-term follow-up of ulcerative colitis patients treated on the basis of their cytomegalovirus antigen status. World J Gastroenterol 2014; 20(2): 509-517 [PMID: 24574719 DOI: 10.3748/wjg.v20.i2.509] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
241 Slonim-nevo V, Sarid O, Friger M, Schwartz D, Sergienko R, Pereg A, Vardi H, Singer T, Chernin E, Greenberg D, Odes S. Effect of threatening life experiences and adverse family relations in ulcerative colitis: analysis using structural equation modeling and comparison with Crohn’s disease. European Journal of Gastroenterology & Hepatology 2017;29:577-86. [DOI: 10.1097/meg.0000000000000826] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
242 Roque Ramos L, DiMaio CJ, Sachar DB, Atreja A, Colombel JF, Torres J. Autoimmune pancreatitis and inflammatory bowel disease: Case series and review of literature. Dig Liver Dis. 2016;48:893-898. [PMID: 27260331 DOI: 10.1016/j.dld.2016.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
243 Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A, Midha V, Gupta V, Choudhuri G, Ahuja V. Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study. Indian J Gastroenterol. 2019;38:44-54. [PMID: 30645725 DOI: 10.1007/s12664-018-0922-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
244 Lenti MV, Armuzzi A, Castiglione F, Fantini MC, Fiorino G, Orlando A, Pugliese D, Rizzello F, Vecchi M, Di Sabatino A. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. Digestive and Liver Disease 2020;52:44-50. [DOI: 10.1016/j.dld.2019.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
245 Nishio M, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scand J Gastroenterol 2018;53:1236-44. [PMID: 30353757 DOI: 10.1080/00365521.2018.1511825] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
246 Boal Carvalho P, Cotter J. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. Drugs. 2017;77:159-173. [PMID: 28078646 DOI: 10.1007/s40265-016-0676-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
247 Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L, Keshav S, Travis S. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis. 2015;9:376-381. [PMID: 25770163 DOI: 10.1093/ecco-jcc/jjv047] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
248 Wu Y, Yang X, Li G, Liu X. Molecular mechanism of Huaihuasan in treatment of ulcerative colitis based on network pharmacology and molecular docking. Phytomedicine Plus 2021;1:100081. [DOI: 10.1016/j.phyplu.2021.100081] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
250 Liu C, Mo LH, Feng BS, Jin QR, Li Y, Lin J, Shu Q, Liu ZG, Liu Z, Sun X, Yang PC. Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. Theranostics 2021;11:7797-812. [PMID: 34335965 DOI: 10.7150/thno.62256] [Reference Citation Analysis]
251 Monteiro S, Dias de Castro F, Boal Carvalho P, Rosa B, Moreira MJ, Pinho R, Saraiva MM, Cotter J. Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified. World J Gastrointest Endosc 2017; 9(1): 34-40 [PMID: 28101306 DOI: 10.4253/wjge.v9.i1.34] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
252 Sonoyama H, Kawashima K, Ishihara S, Kotani S, Fukuba N, Oka A, Kusunoki R, Tada Y, Mishima Y, Oshima N, Moriyama I, Yuki T, Onishi K, Kinoshita Y. Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type. J Clin Biochem Nutr 2019;64:265-70. [PMID: 31138962 DOI: 10.3164/jcbn.18-92] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
253 Zhao Y, Chen B, He Y, Zhang S, Qiu Y, Feng R, Yang H, Zeng Z, Ben-Horin S, Chen M, Mao R. Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease. Intest Res 2020;18:200-9. [PMID: 32224833 DOI: 10.5217/ir.2019.00103] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
254 Rahmani F, Asgharzadeh F, Avan A, Barneh F, Parizadeh MR, Ferns GA, Ryzhikov M, Ahmadian MR, Giovannetti E, Jafari M, Khazaei M, Hassanian SM. Rigosertib potently protects against colitis-associated intestinal fibrosis and inflammation by regulating PI3K/AKT and NF-κB signaling pathways. Life Sciences 2020;249:117470. [DOI: 10.1016/j.lfs.2020.117470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
255 Pillet S, Jarlot C, Courault M, Del Tedesco E, Chardon R, Saint-Sardos P, Presles E, Phelip JM, Berthelot P, Pozzetto B, Roblin X. Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis. Inflamm Bowel Dis. 2015;21:1580-1586. [PMID: 25933392 DOI: 10.1097/mib.0000000000000412] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
256 Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. Journal of Crohn's and Colitis 2018;12:662-9. [DOI: 10.1093/ecco-jcc/jjy028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
257 Seo H, Chang K, Lee S, Song E, Kim G, Seo M, Lee H, Hwang S, Yang D, Kim K, Ye BD, Byeon J, Myung S, Yang S, Park SH. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. Scandinavian Journal of Gastroenterology 2017;52:857-63. [DOI: 10.1080/00365521.2017.1323229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
258 Nazareth N, Magro F, Appelberg R, Silva J, Gracio D, Coelho R, Cabral JM, Abreu C, Macedo G, Bull TJ, Sarmento A. Increased viability but decreased culturability of Mycobacterium avium subsp. paratuberculosis in macrophages from inflammatory bowel disease patients under Infliximab treatment. Med Microbiol Immunol 2015;204:647-56. [PMID: 25702170 DOI: 10.1007/s00430-015-0393-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
259 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Wong SH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Tong RW, Chow WH, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Natural History of Elderly-onset Ulcerative Colitis: Results from a Territory-wide Inflammatory Bowel Disease Registry. J Crohns Colitis 2016;10:176-85. [PMID: 26512132 DOI: 10.1093/ecco-jcc/jjv194] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
260 Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Graziani MG, Lorenzetti R, Luzza F, Paese P, Penna A, Pica R, Pranzo G, Rodinò S, Scarcelli A, Zampaletta C, Brozzi L, Cicerone C, Cocco A, De' Angelis G, Donnarumma L, Fiorella S, Iannelli C, Larussa T, Le Grazie M, Luppino I, Meucci C, FaggianI R, Pagnini C, Perazzo P, Rodriguez-Castro KI, Sacco R, Sebkova L, Serio M, De Monti A, Picchio M, Napolitano D, Schiavoni E, Turchini L, Scaldaferri F, Pugliese D, Guidi L, Laterza L, Privitera G, Pizzoferrato M, Lopetuso LR, Armuzzi A, Elisei W, Maconi G, Papa A. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opin Biol Ther 2021;:1-8. [PMID: 34904510 DOI: 10.1080/14712598.2022.2007881] [Reference Citation Analysis]
261 Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study. United European Gastroenterol J 2021;9:102-9. [PMID: 33203342 DOI: 10.1177/2050640620974308] [Reference Citation Analysis]
262 Zhou JQ, Zeng L, Zhang Q, Wu XY, Zhang ML, Jing XT, Wang YF, Gan HT. Clinical features of Epstein-Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease. Saudi J Gastroenterol 2020. [PMID: 33078719 DOI: 10.4103/sjg.SJG_30_20] [Reference Citation Analysis]
263 Ferreira-Duarte M, Rodrigues-Pinto T, Menezes-Pinto D, Esteves-Monteiro M, Gonçalves-Monteiro S, Capas-Peneda S, Magro F, Dias-Pereira P, Morato M, Duarte-Araújo M. 2,4,6-trinitrobenzenesulfonic acid-induced colitis in Rattus norgevicus: a categorization proposal. Exp Anim 2021;70:245-56. [PMID: 33536378 DOI: 10.1538/expanim.20-0113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Cassieri C, Brandimarte G, Elisei W, Lecca GP, Goni E, Penna A, Picchio M, Tursi A. How to Differentiate Segmental Colitis Associated With Diverticulosis and Inflammatory Bowel Diseases. J Clin Gastroenterol. 2016;50 Suppl 1:S36-S38. [PMID: 27622359 DOI: 10.1097/mcg.0000000000000630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
265 Simon M. Rectocolite hémorragique: traitement médical. Colon Rectum 2013;7:11-7. [DOI: 10.1007/s11725-013-0434-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
266 Rispo A, Testa A, De Palma GD, Donetto S, Diaferia M, Musto D, Nardone O, Maione F, Caporaso N, Castiglione F. Different Profile of Efficacy of Thiopurines in Ulcerative Colitis and Crohn’s Disease. Inflamm Bowel Dis. 2015;21:2570-2575. [PMID: 26222340 DOI: 10.1097/mib.0000000000000538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
267 Minami N, Yoshino T, Matsuura M, Koshikawa Y, Yamada S, Toyonaga T, Madian A, Honzawa Y, Nakase H. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2015;2:e000021. [PMID: 26462273 DOI: 10.1136/bmjgast-2014-000021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
268 Bojic D, Bodger K, Travis S. Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data. J Crohns Colitis. 2017;11:S576-S585. [PMID: 27797917 DOI: 10.1093/ecco-jcc/jjw187] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
269 Kim AH, Roberts C, Feagan BG, Banerjee R, Bemelman W, Bodger K, Derieppe M, Dignass A, Driscoll R, Fitzpatrick R, Gaarentstroom-Lunt J, Higgins PD, Kotze PG, Meissner J, O'Connor M, Ran ZH, Siegel CA, Terry H, van Deen WK, van der Woude CJ, Weaver A, Yang SK, Sands BE, Vermeire S, Travis SP. Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus. J Crohns Colitis 2018;12:408-18. [PMID: 29216349 DOI: 10.1093/ecco-jcc/jjx161] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 14.0] [Reference Citation Analysis]
270 Freitas TH, Andreoulakis E, Alves GS, Miranda HL, Braga LL, Hyphantis T, Carvalho AF. Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease. World J Gastroenterol 2015; 21(21): 6713-6727 [PMID: 26074710 DOI: 10.3748/wjg.v21.i21.6713] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
271 Shi HY, Ng SC, Tsoi KK, Wu JC, Sung JJ, Chan FK. The role of capsule endoscopy in assessing mucosal inflammation in ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:47-54. [PMID: 24966092 DOI: 10.1586/17474124.2014.934359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
272 Sehgal P, Ungaro RC, Foltz C, Iacoviello B, Dubinsky MC, Keefer L. High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021;27:791-6. [PMID: 32696966 DOI: 10.1093/ibd/izaa196] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
273 Shi HY, Chan FKL, Higashimori A, Kyaw M, Ching JYL, Chan HCH, Chan JCH, Chan AWH, Lam KLY, Tang RSY. A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointest Endosc. 2017;86:1139-1146.e6. [PMID: 28713062 DOI: 10.1016/j.gie.2017.07.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
274 Luo XP, Mao R, Chen BL, Qiu Y, Zhang SH, He Y, Chen J, Zeng ZR, Ben-Horin S, Chen MH. Over-reaching beyond disease activity: the influence of anxiety and medical economic burden on health-related quality of life in patients with inflammatory bowel disease. Patient Prefer Adherence 2017;11:23-31. [PMID: 28053510 DOI: 10.2147/PPA.S118589] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
275 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
276 Gasparetto M, Guariso G, Pozza LV, Ross A, Heuschkel R, Zilbauer M. Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy. BMC Gastroenterol 2016;16:35. [PMID: 26976427 DOI: 10.1186/s12876-016-0455-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
277 Mijac D, Vukovic-Petrovic I, Mijac V, Perovic V, Milic N, Djuranovic S, Bojic D, Popovic D, Culafic D, Krstic M, Jankovic G, Pravica V, Markovic M. MDR1 gene polymorphisms are associated with ulcerative colitis in a cohort of Serbian patients with inflammatory bowel disease. PLoS One 2018;13:e0194536. [PMID: 29543864 DOI: 10.1371/journal.pone.0194536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
278 Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, van der Wouden EJ, Dijkstra G, (ICC) RKWDIOCAC. Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol 2014; 20(41): 15374-15381 [PMID: 25386087 DOI: 10.3748/wjg.v20.i41.15374] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
279 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
280 Wang X, Zhu Y, Zhang M, Wang H, Jiang Y, Gao P. Ulcerative Colitis Is Characterized by a Decrease in Regulatory B Cells. J Crohns Colitis 2016;10:1212-23. [PMID: 26980839 DOI: 10.1093/ecco-jcc/jjw074] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
281 Viazis N, Giakoumis M, Bamias G, Goukos D, Koukouratos T, Katopodi K, Karatzas P, Triantos C, Tsolias C, Theocharis G, Daikos GL, Ladas SD, Karamanolis DG, Mantzaris GJ. Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF. Dig Liver Dis 2017;49:29-33. [PMID: 27866814 DOI: 10.1016/j.dld.2016.10.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
282 Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. Dig Dis Sci 2017;62:1305-12. [PMID: 28281165 DOI: 10.1007/s10620-017-4511-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
283 Garcia PG, Chebli LA, da Rocha Ribeiro TC, Gaburri PD, de Lima Pace FH, Barbosa KVBD, Costa LA, de Almeida Cruz W, de Assis IC, Moraes BRM, Zanini A, Chebli JMF. Impact of superimposed Clostridium difficile infection in Crohn’s or ulcerative colitis flares in the outpatient setting. Int J Colorectal Dis 2018;33:1285-94. [DOI: 10.1007/s00384-018-3105-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
284 Guarini A, Biagini S, Capaldi A, Carretto D, Angelis A, Iudice S, Martino G, Marziali B, Mattiola R, Ongarelli C, Onidi FM, Prinzio M, Puthiavettil R, Sardi R, Schiavoni E, Sinatora R, Zullo A. Satisfaction and expectations of patients with inflammatory bowel disease on biologic therapy: a multicenter study. Ann Gastroenterol 2017;30:96-100. [PMID: 28042244 DOI: 10.20524/aog.2016.0100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
285 Martínez-Feito A, Bravo-Gallego LY, Hernández-Breijo B, Diez J, García-Ramirez L, Jaquotot M, Plasencia-Rodríguez C, Nozal P, Mezcua A, Martín-Arranz MD, Pascual-Salcedo D. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar. Sci Rep 2020;10:17099. [PMID: 33051546 DOI: 10.1038/s41598-020-74235-1] [Reference Citation Analysis]
286 Moller FT, Knudsen L, Harbord M, Satsangi J, Gordon H, Christiansen L, Christensen K, Jess T, Andersen V. Danish cohort of monozygotic inflammatory bowel disease twins: Clinical characteristics and inflammatory activity. World J Gastroenterol 2016; 22(21): 5050-5059 [PMID: 27275097 DOI: 10.3748/wjg.v22.i21.5050] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
287 La Barbera D, Bonanno B, Rumeo MV, Alabastro V, Frenda M, Massihnia E, Morgante MC, Sideli L, Craxì A, Cappello M, Tumminello M, Miccichè S, Nastri L. Alexithymia and personality traits of patients with inflammatory bowel disease. Sci Rep 2017;7:41786. [PMID: 28150800 DOI: 10.1038/srep41786] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
288 Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. Inflamm Bowel Dis. 2016;22:2977-2987. [PMID: 27636380 DOI: 10.1097/mib.0000000000000926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
289 Tsuda S, Kunisaki R, Kato J, Murakami M, Nishio M, Ogashiwa T, Yoshida T, Kimura H, Kitano M. Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis. Intest Res 2018;16:579-87. [PMID: 30301332 DOI: 10.5217/ir.2018.00021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
290 Prager M, Durmus T, Büttner J, Molnar T, de Jong DJ, Drenth JP, Baumgart DC, Sturm A, Farkas K, Witt H, Büning C. Myosin IXb variants and their pivotal role in maintaining the intestinal barrier: A study in Crohn’s disease. Scandinavian Journal of Gastroenterology 2014;49:1191-200. [DOI: 10.3109/00365521.2014.928903] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
291 Hirayama A, Joshita S, Kitahara K, Mukawa K, Suga T, Umemura T, Tanaka E, Ota M. Lymphocyte Antigen 75 Polymorphisms Are Associated with Disease Susceptibility and Phenotype in Japanese Patients with Inflammatory Bowel Disease. Dis Markers 2016;2016:6485343. [PMID: 27965521 DOI: 10.1155/2016/6485343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
292 Lucendo AJ, Hervías D, Roncero Ó, Lorente R, Bouhmidi A, Angueira T, Verdejo C, Salueña I, González-Castillo S, Arias Á. Epidemiology and temporal trends (2000-2012) of inflammatory bowel disease in adult patients in a central region of Spain. Eur J Gastroenterol Hepatol 2014;26:1399-407. [PMID: 25341061 DOI: 10.1097/MEG.0000000000000226] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
293 Mocciaro F, Di Mitri R, Russo G, Leone S, Quercia V. Motivational interviewing in inflammatory bowel disease patients: A useful tool for outpatient counselling. Digestive and Liver Disease 2014;46:893-7. [DOI: 10.1016/j.dld.2014.07.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
294 Hussey M, Mc Garrigle R, Kennedy U, Holleran G, Kevans D, Ryan B, Breslin N, Mahmud N, McNamara D. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2016;28:217-221. [PMID: 26587866 DOI: 10.1097/meg.0000000000000515] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
295 Agraib LM, Yamani MI, Rayyan YM, Abu-Sneineh AT, Tamimi TA, Tayyem RF. The probiotic supplementation role in improving the immune system among people with ulcerative colitis: a narrative review. Drug Metab Pers Ther 2021;37:7-19. [PMID: 35385892 DOI: 10.1515/dmpt-2021-0150] [Reference Citation Analysis]
296 Agarwal A, Kedia S, Jain S, Gupta V, Bopanna S, Yadav DP, Goyal S, Mouli VP, Dhingra R, Makharia G, Ahuja V. High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India. Intest Res 2018;16:588-98. [PMID: 30301331 DOI: 10.5217/ir.2018.00023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
297 Llaó J, Naves JE, Ruiz-Cerulla A, Gordillo J, Mañosa M, Maisterra S, Cabré E, Garcia-Planella E, Guardiola J, Domènech E. Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Dig Liver Dis 2016;48:608-12. [PMID: 27012443 DOI: 10.1016/j.dld.2016.02.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
298 Rodrigues-pinto E, Magro F, Pimenta S, Guimarães J, Macedo G. Mimicry between intestinal Behçet's disease and inflammatory bowel disease. Journal of Crohn's and Colitis 2014;8:714-5. [DOI: 10.1016/j.crohns.2013.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
299 Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, Nydegger A, Vavricka SR, Moradpour D, Schoepfer AM; Swiss IBD Cohort Study Group. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur J Gastroenterol Hepatol 2017;29:91-7. [PMID: 27622999 DOI: 10.1097/MEG.0000000000000747] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
300 Assadi G, Saleh R, Hadizadeh F, Vesterlund L, Bonfiglio F, Halfvarson J, Törkvist L, Eriksson AS, Harris HE, Sundberg E, D'Amato M. LACC1 polymorphisms in inflammatory bowel disease and juvenile idiopathic arthritis. Genes Immun 2016;17:261-4. [PMID: 27098602 DOI: 10.1038/gene.2016.17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
301 Corte CJ, Leong RW. Improving the utility of colonoscopy: Recent advances in practice. J Gastroenterol Hepatol. 2016;31:32-44. [PMID: 26211821 DOI: 10.1111/jgh.13056] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
302 Teixeira FV, Hosne RS, Sobrado CW. Management of ulcerative colitis: a clinical update. Journal of Coloproctology 2021;35:230-7. [DOI: 10.1016/j.jcol.2015.08.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
303 Kedia S, Ghosh TS, Jain S, Desigamani A, Kumar A, Gupta V, Bopanna S, Yadav DP, Goyal S, Makharia G, Travis SPL, Das B, Ahuja V. Gut microbiome diversity in acute severe colitis is distinct from mild to moderate ulcerative colitis. J Gastroenterol Hepatol 2021;36:731-9. [PMID: 32870508 DOI: 10.1111/jgh.15232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
304 Spiller R, Major G. IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol. 2016;13:613-621. [PMID: 27667579 DOI: 10.1038/nrgastro.2016.141] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 14.0] [Reference Citation Analysis]
305 Can G, Poşul E, Yılmaz B, Can H, Korkmaz U, Ermiş F, Kurt M, Dağlı Ü. Epidemiologic features of ınflammatory bowel disease in Western Blacksea region of Turkey for the last 10 years: retrospective cohort study. Korean J Intern Med 2019;34:519-29. [PMID: 29695147 DOI: 10.3904/kjim.2015.310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
306 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
307 Huoponen S, Blom M. A Systematic Review of the Cost-Effectiveness of Biologics for the Treatment of Inflammatory Bowel Diseases. PLoS One 2015;10:e0145087. [PMID: 26675292 DOI: 10.1371/journal.pone.0145087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
308 Lee SY, Lee SH, Yang EJ, Kim EK, Kim JK, Shin DY, Cho ML. Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance. PLoS One. 2015;10:e0135858. [PMID: 26360050 DOI: 10.1371/journal.pone.0135858] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
309 Bjerrum JT, Steenholdt C, Ainsworth M, Nielsen OH, Reed MA, Atkins K, Günther UL, Hao F, Wang Y. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med 2017;15:184. [PMID: 29032767 DOI: 10.1186/s12916-017-0949-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
310 Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X. French national consensus clinical guidelines for the management of ulcerative colitis. Dig Liver Dis. 2016;48:726-733. [PMID: 27158125 DOI: 10.1016/j.dld.2016.03.029] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
311 Lenti MV, Selinger CP. Medication non-adherence in adult patients affected by inflammatory bowel disease: a critical review and update of the determining factors, consequences and possible interventions. Expert Rev Gastroenterol Hepatol 2017;11:215-26. [PMID: 28099821 DOI: 10.1080/17474124.2017.1284587] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
312 Yu Q, Zhang S, Chao K, Feng R, Wang H, Li M, Chen B, He Y, Zeng Z, Chen M. E3 Ubiquitin ligase RNF183 Is a Novel Regulator in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:713-725. [PMID: 26818663 DOI: 10.1093/ecco-jcc/jjw023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
313 Tan CXW, Brand HS, Iqbal S, De Boer NKH, Forouzanfar T, de Visscher JGAM. A self-reported survey on oral health problems in patients with inflammatory bowel disease with a stoma. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130:e80-6. [PMID: 32601008 DOI: 10.1016/j.oooo.2020.04.816] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Zamani S, Hesam Shariati S, Zali MR, Asadzadeh Aghdaei H, Sarabi Asiabar A, Bokaie S, Nomanpour B, Sechi LA, Feizabadi MM. Detection of enterotoxigenic Bacteroides fragilis in patients with ulcerative colitis. Gut Pathog 2017;9:53. [PMID: 28924454 DOI: 10.1186/s13099-017-0202-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
315 Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, Buchel OC, White L, Brain O, Keshav S, Warren BF, Travis SP. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65:408-414. [PMID: 25986946 DOI: 10.1136/gutjnl-2015-309598] [Cited by in Crossref: 190] [Cited by in F6Publishing: 173] [Article Influence: 27.1] [Reference Citation Analysis]
316 Carter D, Eliakim R. PillCam colon capsule endoscopy (PCCE) in colonic diseases. Ann Transl Med 2016;4:307. [PMID: 27668227 DOI: 10.21037/atm.2016.08.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
317 Jeuring SFG, Bours PHA, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-camps MJL, van Bodegraven AA, Oostenbrug LE, Breukink SO, Stassen LPS, Hameeteman WH, Masclee AAM, Jonkers DMAE, Pierik MJ. Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort. ECCOJC 2015;9:837-45. [DOI: 10.1093/ecco-jcc/jjv129] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 5.1] [Reference Citation Analysis]
318 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.7] [Reference Citation Analysis]
319 Frieri G, Galletti B, Di Ruscio M, Tittoni R, Capannolo A, Serva D, Latella G, Sollima L, Leocata P, Necozione S, Frieri R, Viscido A. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine. Therap Adv Gastroenterol 2017;10:749-59. [PMID: 29051786 DOI: 10.1177/1756283X17722926] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
320 Tanida S, Mizoshita T, Nishie H, Ozeki K, Katano T, Kubota E, Kataoka H, Kamiya T, Joh T. Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis. J Clin Med Res. 2015;7:884-889. [PMID: 26491502 DOI: 10.14740/jocmr2333w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
321 Yeshi K, Ruscher R, Hunter L, Daly NL, Loukas A, Wangchuk P. Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products. J Clin Med 2020;9:E1273. [PMID: 32354192 DOI: 10.3390/jcm9051273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
322 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Forti G, Franceschi M, Ferronato A, Gallina S, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Ricciardelli C, Zampaletta C, Elisei W, Picchio M. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol 2019;32:392-9. [PMID: 31263362 DOI: 10.20524/aog.2019.0377] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
323 Scaioli E, Scagliarini M, Cardamone C, Liverani E, Ugolini G, Festi D, Bazzoli F, Belluzzi A. Clinical application of faecal calprotectin in ulcerative colitis patients. Eur J Gastroenterol Hepatol. 2015;27:1418-1424. [PMID: 26308711 DOI: 10.1097/meg.0000000000000461] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
324 Moisset X, Bommelaer G, Boube M, Ouchchane L, Goutte M, Dapoigny M, Dallel R, Guttmann A, Clavelou P, Buisson A. Migraine prevalence in inflammatory bowel disease patients: A tertiary-care centre cross-sectional study. Eur J Pain 2017;21:1550-60. [DOI: 10.1002/ejp.1056] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
325 Ning L, Li S, Gao J, Ding L, Wang C, Chen W, Shan G, Zhang F, Yu J, Xu G. Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy.Biomed Res Int. 2019;2019:1475705. [PMID: 31886172 DOI: 10.1155/2019/1475705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
326 Gashin L, Villafuerte-galvez J, Leffler DA, Obuch J, Cheifetz AS. Utility of CT in the Emergency Department in Patients with Ulcerative Colitis: . Inflammatory Bowel Diseases 2015;21:793-800. [DOI: 10.1097/mib.0000000000000321] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
327 Hoy SM. Budesonide MMX(®): a review of its use in patients with mild to moderate ulcerative colitis. Drugs. 2015;75:879-886. [PMID: 25920500 DOI: 10.1007/s40265-015-0396-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
328 Ventham NT, Kalla R, Kennedy NA, Satsangi J, Arnott ID. Predicting outcomes in acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2015;9:405-415. [PMID: 25494666 DOI: 10.1586/17474124.2015.992880] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
329 Lopes S, Andrade P, Conde S, Liberal R, Dias CC, Fernandes S, Pinheiro J, Simões JS, Carneiro F, Magro F, Macedo G. Looking into Enteric Virome in Patients with IBD: Defining Guilty or Innocence? Inflammatory Bowel Diseases 2017;23:1278-84. [DOI: 10.1097/mib.0000000000001167] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 4.4] [Reference Citation Analysis]
330 Kucharzik T, Dignass AU, Atreya R, Bokemeyer B, Esters P, Herrlinger K, Kannengießer K, Kienle P, Langhorst J, Lügering A, Schreiber S, Stallmach A, Stein J, Sturm A, Teich N, Siegmund B; Collaborators:. Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Z Gastroenterol 2020;58:e241-326. [PMID: 33260237 DOI: 10.1055/a-1296-3444] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
331 O'connor M, Bager P, Duncan J, Gaarenstroom J, Younge L, Détré P, Bredin F, Dibley L, Dignass A, Gallego Barrero M, Greveson K, Hamzawi M, Ipenburg N, Keegan D, Martinato M, Murciano Gonzalo F, Pino Donnay S, Price T, Ramirez Morros A, Verwey M, White L, van de Woude C. N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. Journal of Crohn's and Colitis 2013;7:744-64. [DOI: 10.1016/j.crohns.2013.06.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
332 Korani S, Korani M, Sathyapalan T, Sahebkar A. Therapeutic effects of Crocin in autoimmune diseases: A review. Biofactors 2019;45:835-43. [PMID: 31430413 DOI: 10.1002/biof.1557] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
333 Chapman S, Sibelli A, St-Clair Jones A, Forbes A, Chater A, Horne R. Personalised Adherence Support for Maintenance Treatment of Inflammatory Bowel Disease: A Tailored Digital Intervention to Change Adherence-related Beliefs and Barriers. J Crohns Colitis 2020;14:1394-404. [PMID: 32379303 DOI: 10.1093/ecco-jcc/jjz034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
334 Boal Carvalho P, Dias de Castro F, Rosa B, Moreira MJ, Cotter J. Mucosal Healing in Ulcerative Colitis--When Zero is Better. J Crohns Colitis. 2016;10:20-25. [PMID: 26438714 DOI: 10.1093/ecco-jcc/jjv180] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
335 Dan A, Boutros M, Nedjar H, Kopylov U, Afif W, Khalil MA, Rahme E. Cost of Ulcerative Colitis in Quebec, Canada: A Retrospective Cohort Study. Inflamm Bowel Dis 2017;23:1262-71. [PMID: 28691933 DOI: 10.1097/MIB.0000000000001147] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
336 Lee SH, Kwon JY, Moon J, Choi J, Jhun J, Jung K, Cho KH, Darlami O, Lee HH, Jung ES, Shin DY, Lee BI, Cho ML. Inhibition of RIPK3 Pathway Attenuates Intestinal Inflammation and Cell Death of Inflammatory Bowel Disease and Suppresses Necroptosis in Peripheral Mononuclear Cells of Ulcerative Colitis Patients. Immune Netw 2020;20:e16. [PMID: 32395368 DOI: 10.4110/in.2020.20.e16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Azzam N, AlRuthia Y, Alharbi O, Aljebreen A, Almadi M, Loftus EV Jr. Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease. Hepatol Int 2020;14:1114-24. [PMID: 33369708 DOI: 10.1007/s12072-020-10110-5] [Reference Citation Analysis]
338 Venkateswaran S, Prince J, Cutler DJ, Marigorta UM, Okou DT, Prahalad S, Mack D, Boyle B, Walters T, Griffiths A, Sauer CG, LeLeiko N, Keljo D, Markowitz J, Baker SS, Rosh J, Pfefferkorn M, Heyman MB, Patel A, Otley A, Baldassano R, Noe J, Rufo P, Oliva-Hemker M, Davis S, Zwick ME, Gibson G, Denson LA, Hyams J, Kugathasan S. Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis. Inflamm Bowel Dis 2018;24:829-38. [PMID: 29562276 DOI: 10.1093/ibd/izx084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
339 Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. The safety of vedolizumab for the treatment of ulcerative colitis.Expert Opin Drug Saf. 2017;16:501-507. [PMID: 28276855 DOI: 10.1080/14740338.2017.1300251] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
340 Kourkoulis P, Michalopoulos G, Katifelis H, Giannopoulou I, Lazaris AC, Papaconstantinou I, Karamanolis G, Gazouli M. Leucine-rich alpha-2 glycoprotein 1, high mobility group box 1, matrix metalloproteinase 3 and annexin A1 as biomarkers of ulcerative colitis endoscopic and histological activity. Eur J Gastroenterol Hepatol 2020;32:1106-15. [PMID: 32483088 DOI: 10.1097/MEG.0000000000001783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
341 Naidu J, Wong Zh, Palaniappan Sh, Ngiu ChS, Yaacob NY, Abdul Hamid H, Hikmah Elias M, Mokhtar NM, Raja Ali RA. Radiation Exposure in Patients with Inflammatory Bowel Disease: a Fourteen-Year Review at a Tertiary Care Centre in Malaysia. Asian Pac J Cancer Prev 2017;18:933-9. [PMID: 28545190 DOI: 10.22034/APJCP.2017.18.4.933] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
342 Asano K, Esaki M, Umeno J, Hirano A, Maehata Y, Moriyama T, Nakamura S, Matsumoto T, Kitazono T. Contribution of susceptibility variants at FCGR2A and 13q12 to the risk of relapse among Japanese patients with ulcerative colitis. J Gastroenterol 2015;50:1094-102. [PMID: 25787843 DOI: 10.1007/s00535-015-1062-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
343 Magro F, Lopes S, Coelho R, Cotter J, de Castro FD, de Sousa HT, Salgado M, Andrade P, Vieira AI, Figueiredo P, Caldeira P, Sousa A, Duarte MA, Ávila F, Silva J, Moleiro J, Mendes S, Giestas S, Ministro P, Sousa P, Gonçalves R, Gonçalves B, Oliveira A, Chagas C, Torres J, Dias CC, Lopes J, Borralho P, Afonso J, Geboes K, Carneiro F; on behalf of the Portuguese IBD Study Group [GEDII]. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis—the ACERTIVE study. ECCOJC. [DOI: 10.1093/ecco-jcc/jjw170] [Reference Citation Analysis]
344 Roselli M, Maruszak A, Grimaldi R, Harthoorn L, Finamore A. Galactooligosaccharide Treatment Alleviates DSS-Induced Colonic Inflammation in Caco-2 Cell Model. Front Nutr 2022;9:862974. [DOI: 10.3389/fnut.2022.862974] [Reference Citation Analysis]
345 Özdirik B, Müller T, Wree A, Tacke F, Sigal M. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies. Int J Mol Sci 2021;22:6975. [PMID: 34203536 DOI: 10.3390/ijms22136975] [Reference Citation Analysis]
346 Agraib LM, Yamani MI, Rayyan YM, Abu-Sneineh AT, Tamimi TA, Tayyem RF. The probiotic supplementation role in improving the immune system among people with ulcerative colitis: a narrative review. Drug Metab Pers Ther 2021. [PMID: 34428363 DOI: 10.1515/dmdi-2021-0150] [Reference Citation Analysis]
347 Uchida K, Araki T, Hashimoto K, Inoue M, Otake K, Koike Y, Okita Y, Fujikawa H, Tanaka K, Mohri Y, Kusunoki M. Segmental distribution in refractory ulcerative colitis: a histological evaluation in pediatric and adult patients who underwent proctocolectomy. Inflamm Bowel Dis 2014;20:1227-35. [PMID: 24865779 DOI: 10.1097/MIB.0000000000000082] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
348 Kedia S, Ahuja V, Makharia GK. Golimumab for moderately to severely active ulcerative colitis. Expert Rev Clin Pharmacol 2016;9:1273-82. [PMID: 27498886 DOI: 10.1080/17512433.2016.1221759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
349 Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology 2017;152:1975-1984.e8. [PMID: 28274849 DOI: 10.1053/j.gastro.2017.02.038] [Cited by in Crossref: 180] [Cited by in F6Publishing: 159] [Article Influence: 36.0] [Reference Citation Analysis]
350 Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, Reich O. Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol 2017;17:138. [PMID: 29197335 DOI: 10.1186/s12876-017-0681-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
351 Lin CC, Wei SC, Lin BR, Tsai WS, Chen JS, Hsu TC, Lin WC, Huang TY, Chao TH, Lin HH, Wong JM, Lin JK. A retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease. Intest Res 2016;14:248-57. [PMID: 27433147 DOI: 10.5217/ir.2016.14.3.248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
352 Marinelli C, Savarino E, Inferrera M, Lorenzon G, Rigo A, Ghisa M, Facchin S, D'Incà R, Zingone F. Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. Gastroenterol Res Pract 2019;2019:5354320. [PMID: 31531015 DOI: 10.1155/2019/5354320] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
353 Facchin S, Buda A, Cardin R, Agbariah N, Zingone F, De Bona M, Zaetta D, Bertani L, Ghisa M, Barberio B, Savarino EV. Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients. Therap Adv Gastroenterol 2021;14:1756284821999902. [PMID: 33815569 DOI: 10.1177/1756284821999902] [Reference Citation Analysis]
354 Dignass A, Akbar A, Baumgart DC, Bommelaer G, Bouguen G, Cadiot G, Gillessen A, Grimaud JC, Hart A, Hoque S, Makins R, Michiels C, Moreau J, Premchand P, Ramlow W, Schanz S, Subramanian S, von Tirpitz C, Bonaz B. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis. Scand J Gastroenterol. 2018;53:442-448. [PMID: 29513111 DOI: 10.1080/00365521.2018.1447598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
355 Langbrandtner J, Hüppe A, Jessen P, Büning J, Nikolaus S, Raspe H, Bokemeyer B. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol 2017;10:215-27. [PMID: 28919797 DOI: 10.2147/CEG.S135346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
356 Keil R, Wasserbauer M, Zádorová Z, Hajer J, Drastich P, Wohl P, Beneš M, Bojková M, Svoboda P, Konečný M, Falt P, Vaňásek T, Pešta M, Pešek F, Bouchner L, Koželuhová J, Novotný A, Bartůsková L, Špičák J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis. Scand J Gastroenterol 2016;51:1062-8. [PMID: 27002981 DOI: 10.3109/00365521.2016.1149883] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
357 Martins KR, Araújo JM, Cruz ÁC, Luiz-Ferreira A. EPIDEMIOLOGIC ASPECTS OF INFLAMMATORY BOWEL DISEASE IN THE WESTERN REGION OF MINAS GERAIS STATE. Arq Gastroenterol 2021;58:377-83. [PMID: 34705974 DOI: 10.1590/S0004-2803.202100000-63] [Reference Citation Analysis]
358 Eberhardson M, Levine YA, Tarnawski L, Olofsson PS. The brain-gut axis, inflammatory bowel disease and bioelectronic medicine. Int Immunol 2021;33:349-56. [PMID: 33912906 DOI: 10.1093/intimm/dxab018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Yee EU, Goldsmith JD. Diarrheal Illness in the Pediatric Population. Surgical Pathology Clinics 2013;6:523-43. [DOI: 10.1016/j.path.2013.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
360 Bengi G, Keyvan H, Durmaz SB, Akpınar H. Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(36): 4186-4196 [PMID: 30271083 DOI: 10.3748/wjg.v24.i36.4186] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
361 Timerbulatov MV, Grishina EE, Aitova LR, Senderovich EI, Ziganshin TM. [The Capsule Endoscopy Crohn's Disease Activity Index, clinical activity and fecal calprotectin level in patients with isolated small intestine lesions]. Khirurgiia (Mosk) 2021;:63-70. [PMID: 34480457 DOI: 10.17116/hirurgia202109163] [Reference Citation Analysis]
362 Lu B, Niu LL, Xu XG, Yao SL, Tan XY. Ulcerative colitis in an adult patient mimicking Henoch-Schönlein purpura: A case report. Medicine (Baltimore) 2018;97:e12036. [PMID: 30170414 DOI: 10.1097/MD.0000000000012036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
363 Ferrer Márquez M, Hernández Martínez Á, Reina Duarte Á, Rosado Cobián R. Current Status of the Treatment of Fulminant Colitis. Cir Esp 2015;93:276-82. [PMID: 25649534 DOI: 10.1016/j.ciresp.2014.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
364 Valmiki S, Ahuja V, Paul J. MicroRNA exhibit altered expression in the inflamed colonic mucosa of ulcerative colitis patients. World J Gastroenterol 2017; 23(29): 5324-5332 [PMID: 28839432 DOI: 10.3748/wjg.v23.i29.5324] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
365 Lv C, Zhao X, Gu H, Huang L, Zhou S, Zhi F. Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms. Med Sci Monit 2016;22:4794-802. [PMID: 27926694 DOI: 10.12659/msm.902274] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
366 Angelison L, Almer S, Davidsdottir L, Hammarlund P, Lindgren S, Hindorf U, Marsal J, Hertervig E. Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study. Scand J Gastroenterol 2020;55:154-62. [PMID: 31961234 DOI: 10.1080/00365521.2020.1713210] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
367 Wei SC, Chang TA, Chao TH, Chen JS, Chou JW, Chou YH, Chuang CH, Hsu WH, Huang TY, Hsu TC, Lin CC, Lin HH, Lin JK, Lin WC, Ni YH, Shieh MJ, Shih IL, Shun CT, Tsang YM, Wang CY, Wang HY, Weng MT, Wu DC, Wu WC, Yen HH, Wong JM. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Intest Res. 2017;15:266-284. [PMID: 28670225 DOI: 10.5217/ir.2017.15.3.266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
368 Nóbrega VG, Silva INN, Brito BS, Silva J, Silva MCMD, Santana GO. THE ONSET OF CLINICAL MANIFESTATIONS IN INFLAMMATORY BOWEL DISEASE PATIENTS. Arq Gastroenterol 2018;55:290-5. [PMID: 30540094 DOI: 10.1590/S0004-2803.201800000-73] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
369 Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol 2015; 21(1): 21-46 [PMID: 25574078 DOI: 10.3748/wjg.v21.i1.21] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 76] [Article Influence: 13.0] [Reference Citation Analysis]
370 Lolli E, Saraceno R, Calabrese E, Ascolani M, Scarozza P, Chiricozzi A, Onali S, Petruzziello C, Chimenti S, Pallone F, Biancone L. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. J Crohns Colitis 2015;9:699-707. [PMID: 25908719 DOI: 10.1093/ecco-jcc/jjv068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
371 Kumawat AK, Strid H, Tysk C, Bohr J, Hörnquist EH. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol. 2013;55:355-364. [PMID: 23566938 DOI: 10.1016/j.molimm.2013.03.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
372 Choi CH, Moon W, Kim YS, Kim ES, Lee B, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of the Intestinal Diseases. Second Korean Guideline for the Management of Ulcerative Colitis. Korean J Gastroenterol 2017;69:1. [DOI: 10.4166/kjg.2017.69.1.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
373 Thomsen KL, Grønbæk H, Dahlerup JF, Aagaard NK, Christensen LA, Agnholt J, Frystyk J, Vilstrup H. Prednisolone but Not Infliximab Aggravates the Upregulated Hepatic Nitrogen Elimination in Patients with Active Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:7-13. [DOI: 10.1097/01.mib.0000437496.07181.4c] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
374 Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
375 Sorrentino D. Preclinical and Undiagnosed Crohnʼs Disease: The Submerged Iceberg. Inflammatory Bowel Diseases 2016;22:476-86. [DOI: 10.1097/mib.0000000000000612] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
376 Fang SY, Li CL, Liu XS, Chen F, Hua H. Correlation between polymorphisms of the NR3C1 gene and glucocorticoid effectiveness in patients with pemphigus vulgaris. Sci Rep 2017;7:11890. [PMID: 28928407 DOI: 10.1038/s41598-017-12255-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
377 Bressler B, Marshall JK, Bernstein CN, Bitton A, Jones J, Leontiadis GI, Panaccione R, Steinhart AH, Tse F, Feagan B; Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035-1058.e3. [PMID: 25747596 DOI: 10.1053/j.gastro.2015.03.001] [Cited by in Crossref: 211] [Cited by in F6Publishing: 180] [Article Influence: 30.1] [Reference Citation Analysis]
378 Shih I, Wei S, Yen R, Chang C, Ko C, Lin B, Shun C, Liu K, Wong J, Chang Y. PET/MRI for evaluating subclinical inflammation of ulcerative colitis: PET/MRI in Ulcerative Colitis. J Magn Reson Imaging 2018;47:737-45. [DOI: 10.1002/jmri.25795] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
379 Devaraj B, Kaiser AM. Surgical management of ulcerative colitis in the era of biologicals. Inflamm Bowel Dis 2015;21:208-20. [PMID: 25222665 DOI: 10.1097/MIB.0000000000000178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
380 Calvet X, Saldaña R, Carpio D, Mínguez M, Vera I, Juliá B, Marín L, Casellas F. Improving Quality of Care in Inflammatory Bowel Disease Through Patients’ Eyes: IQCARO Project. Inflammatory Bowel Diseases 2020;26:782-91. [DOI: 10.1093/ibd/izz126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
381 Walsh A, Kormilitzin A, Hinds C, Sexton V, Brain O, Keshav S, Uhlig H, Geddes J, Goodwin G, Peters M, Collins G, Travis S. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis. J Crohns Colitis 2019;13:424-30. [PMID: 30445625 DOI: 10.1093/ecco-jcc/jjy184] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
382 Tasende MM, Delgado S, Jimenez M, Del Gobbo GD, Fernández-Hevia M, DeLacy B, Balust J, Lacy AM. Minimal invasive surgery: NOSE and NOTES in ulcerative colitis. Surg Endosc. 2015;29:3313-3318. [PMID: 25669637 DOI: 10.1007/s00464-015-4087-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
383 Zhang ZM, Li W, Jiang XL. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut Liver. 2016;10:262-274. [PMID: 26780088 DOI: 10.5009/gnl15042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
384 Bryant RV, Friedman AB, Wright EK, Taylor KM, Begun J, Maconi G, Maaser C, Novak KL, Kucharzik T, Atkinson NSS, Asthana A, Gibson PR. Gastrointestinal ultrasound in inflammatory bowel disease: an underused resource with potential paradigm-changing application. Gut. 2018;67:973-985. [PMID: 29437914 DOI: 10.1136/gutjnl-2017-315655] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
385 Sahu P, Jain S, Kedia S, Vuyyuru SK, Sahni P, Sharma R, Panwar R, Das P, Gupta V, Makharia G, Travis S, Ahuja V. Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. Indian J Gastroenterol 2022. [PMID: 35474175 DOI: 10.1007/s12664-021-01217-0] [Reference Citation Analysis]
386 Soubières AA, Poullis A. Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2016; 7(1): 41-50 [PMID: 26855811 DOI: 10.4292/wjgpt.v7.i1.41] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
387 Yoshino T, Yamakawa K, Nishimura S, Watanabe K, Yazumi S. The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing. Intest Res 2016;14:37-42. [PMID: 26884733 DOI: 10.5217/ir.2016.14.1.37] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
388 American Society for Gastrointestinal Endoscopy Standards of Practice Committee. , Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fonkalsrud L, Foley K, Hwang JH, Jue TL, Khashab MA, Muthusamy VR, Pasha SF, Saltzman JR, Sharaf R, Cash BD, DeWitt JM. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc 2015; 81: 1101-21. e1-13. [PMID: 25800660 DOI: 10.1016/j.gie.2014.10.030] [Cited by in Crossref: 172] [Cited by in F6Publishing: 152] [Article Influence: 24.6] [Reference Citation Analysis]
389 Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L. Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterol 2016;3:e000092. [PMID: 27239329 DOI: 10.1136/bmjgast-2016-000092] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
390 Fumery M, Xiaocang C, Dauchet L, Gower-rousseau C, Peyrin-biroulet L, Colombel J. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: A meta-analysis of observational studies. Journal of Crohn's and Colitis 2014;8:469-79. [DOI: 10.1016/j.crohns.2013.09.021] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 11.0] [Reference Citation Analysis]
391 Andersen V, Svenningsen K, Knudsen LA, Hansen AK, Holmskov U, Stensballe A, Vogel U. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. World J Gastroenterol 2015; 21(41): 11862-11876 [PMID: 26557010 DOI: 10.3748/wjg.v21.i41.11862] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
392 Kalubowila U, Liyanaarachchi T, Galketiya KB, Rathnayaka P, Piyasena INAP, Tennakoon S, Perera KMP, Pathirana SDMU, Wettewa DB, Ratnayake WRANMP, Raayiz RM, Dissanayaka DMIU. Epidemiology and clinical course of inflammatory bowel disease in the Central Province of Sri Lanka: A hospital-based study. JGH Open. 2018;2:129-133. [PMID: 30483577 DOI: 10.1002/jgh3.12058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
393 Rezaei N, Avan A, Pashirzad M, Rahmani F, Moradi Marjaneh R, Behnam-Rassouli R, Shafiee M, Ryzhikov M, Hashemzehi M, Ariakia F, Bahreyni A, Hassanian SM, Khazaei M. Crocin as a novel therapeutic agent against colitis. Drug Chem Toxicol 2020;43:514-21. [PMID: 30714419 DOI: 10.1080/01480545.2018.1527850] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
394 Chen M, Liu XL, Zhang YJ, Nie YZ, Wu KC, Shi YQ. Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis. J Dig Dis 2020;21:621-8. [PMID: 32909356 DOI: 10.1111/1751-2980.12938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
395 Maione F, Giglio MC, Luglio G, Rispo A, D'Armiento M, Manzo B, Cassese G, Schettino P, Gennarelli N, Siciliano S, D'Armiento FP, De Palma GD. Confocal laser endomicroscopy in ulcerative colitis: beyond endoscopic assessment of disease activity. Tech Coloproctol 2017;21:531-40. [PMID: 28674950 DOI: 10.1007/s10151-017-1654-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
396 Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, Ferrante M, Marteau P, Zmora O, Kotze PG, Espin-basany E, Tiret E, Sica G, Panis Y, Faerden AE, Biancone L, Angriman I, Serclova Z, de Buck van Overstraeten A, Gionchetti P, Stassen L, Warusavitarne J, Adamina M, Dignass A, Eliakim R, Magro F, D’hoore A. European evidence based consensus on surgery for ulcerative colitis. Journal of Crohn's and Colitis 2015;9:4-25. [DOI: 10.1016/j.crohns.2014.08.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 137] [Article Influence: 23.3] [Reference Citation Analysis]
397 Pavlides M, Cleland J, Rahman M, Christian A, Doyle J, Gaunt R, Travis S, Mortensen N, Chapman R. Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. J Crohns Colitis. 2014;8:662-670. [PMID: 24418660 DOI: 10.1016/j.crohns.2013.12.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
398 Nebbia M, Yassin NA, Spinelli A. Colorectal Cancer in Inflammatory Bowel Disease. Clin Colon Rectal Surg 2020;33:305-17. [PMID: 32968366 DOI: 10.1055/s-0040-1713748] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
399 Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, Fiorino G, Nardone OM, De Vitis I. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. Inflamm Bowel Dis. 2014;20:1368-1374. [PMID: 24983979 DOI: 10.1097/mib.0000000000000115] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
400 Choi CH, Moon W, Kim YS, Kim ES, Lee BI, Jung Y, Yoon YS, Lee H, Park DI, Han DS; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Second Korean guidelines for the management of ulcerative colitis. Intest Res. 2017;15:7-37. [PMID: 28239313 DOI: 10.5217/ir.2017.15.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 7.4] [Reference Citation Analysis]
401 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
402 Macaluso FS, Renna S, Maida M, Dimarco M, Sapienza C, Affronti M, Orlando E, Rizzuto G, Orlando R, Ventimiglia M, Cottone M, Orlando A. Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scandinavian Journal of Gastroenterology 2017. [DOI: 10.1080/00365521.2017.1333626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
403 Cesarini M, Collins GS, Rönnblom A, Santos A, Wang LM, Sjöberg D, Parkes M, Keshav S, Travis SP. Predicting the Individual Risk of Acute Severe Colitis at Diagnosis. J Crohns Colitis 2017;11:335-41. [PMID: 27647858 DOI: 10.1093/ecco-jcc/jjw159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
404 Sarlos P, Kovesdi E, Magyari L, Banfai Z, Szabo A, Javorhazy A, Melegh B. Genetic update on inflammatory factors in ulcerative colitis: Review of the current literature. World J Gastrointest Pathophysiol 2014; 5(3): 304-321 [PMID: 25133031 DOI: 10.4291/wjgp.v5.i3.304] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
405 Gasparetto M, Zilbauer M. Paediatric Inflammatory Bowel Diseases – brief update on current practice and future perspectives. Paediatrics and Child Health 2014;24:501-5. [DOI: 10.1016/j.paed.2014.04.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
406 da Silva BC, Lyra AC, Mendes CM, Ribeiro CP, Lisboa SR, de Souza MT, Portela RC, Santana GO. The Demographic and Clinical Characteristics of Ulcerative Colitis in a Northeast Brazilian Population. Biomed Res Int. 2015;2015:359130. [PMID: 26509150 DOI: 10.1155/2015/359130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
407 Parisi I, O'Beirne J, Rossi RE, Tsochatzis E, Manousou P, Theocharidou E, Hamilton M, Murray C, Epstein O, Burroughs AK. Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab. Eur J Gastroenterol Hepatol 2016;28:786-91. [PMID: 27015138 DOI: 10.1097/MEG.0000000000000624] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
408 Smids C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, Wahab PJ, van Lochem EG. The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient. Scand J Gastroenterol. 2017;52:1104-1112. [PMID: 28661185 DOI: 10.1080/00365521.2017.1344875] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
409 Armuzzi A, Liguori G. Quality of life in patients with moderate to severe ulcerative colitis and the impact of treatment: A narrative review. Dig Liver Dis 2021;53:803-8. [PMID: 33744172 DOI: 10.1016/j.dld.2021.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
410 Günaltay S, Nyhlin N, Kumawat AK, Tysk C, Bohr J, Hultgren O, Hörnquist EH. Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis. World J Gastroenterol 2014; 20(34): 12249-12259 [PMID: 25232259 DOI: 10.3748/wjg.v20.i34.12249] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
411 Zanoli L, Lentini P, Boutouyrie P, Fatuzzo P, Granata A, Corrao S, Gaudio A, Inserra G, Rapisarda F, Rastelli S, Laurent S, Malatino LS, Castellino P. Pulse wave velocity differs between ulcerative colitis and chronic kidney disease. European Journal of Internal Medicine 2018;47:36-42. [DOI: 10.1016/j.ejim.2017.08.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
412 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756-1770. [PMID: 27914657 DOI: 10.1016/s0140-6736(16)32126-2] [Cited by in Crossref: 830] [Cited by in F6Publishing: 381] [Article Influence: 138.3] [Reference Citation Analysis]
413 Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 36] [Article Influence: 27.0] [Reference Citation Analysis]
414 Lucendo AJ, Arias Á, Roncero Ó, Hervías D, Verdejo C, Naveas-Polo C, Bouhmidi A, Lorente R, Alcázar LM, Salueña I, García-Quiñones JA, Carrillo-Ramos MJ. Anemia at the time of diagnosis of inflammatory bowel disease: Prevalence and associated factors in adolescent and adult patients. Dig Liver Dis 2017;49:405-11. [PMID: 28096058 DOI: 10.1016/j.dld.2016.12.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
415 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
416 Zacharias P, Damião AOMC, Moraes AC, Teixeira FV, Ludvig JC, Nones RB, Saad-Hossne R, Sassaki LY, Silva RPLD, Facchin L, Olandoski M, Kotze PG. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. Arq Gastroenterol 2017;54:321-7. [PMID: 28977114 DOI: 10.1590/S0004-2803.201700000-51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
417 Chen XL, Deng J, Chen X, Wan SS, Wang Y, Cao Q. High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: A prospective observational cohort study. J Dig Dis 2019;20:460-6. [DOI: 10.1111/1751-2980.12798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
418 Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis 2017;23:233-43. [PMID: 28092307 DOI: 10.1097/MIB.0000000000000995] [Cited by in Crossref: 96] [Cited by in F6Publishing: 28] [Article Influence: 24.0] [Reference Citation Analysis]
419 Aguas Peris M, Bosó V, Navarro B, Marqués-Miñana MR, Bastida G, Beltrán B, Iborra M, Sáez-González E, Monte-Boquet E, Poveda-Andrés JL, Nos P. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice. Inflamm Bowel Dis 2017;23:1454-60. [PMID: 28708805 DOI: 10.1097/MIB.0000000000001182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
420 Bonnaud G, Haennig A, Levy J, Sigur N, Ledit A, Cabarrot P, Faure P, Auzimour C, El Atmani A, Hebuterne X, Peyrin-Biroulet L. Implementation of the French national consensus for the management of ulcerative colitis into clinical practice. Dig Liver Dis 2016;48:1405-9. [PMID: 27697417 DOI: 10.1016/j.dld.2016.08.127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
421 Gionchetti P, Rizzello F, Annese V, Armuzzi A, Biancone L, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Incà R, Fries W, Kohn A, Orlando A, Papi C, Vecchi M, Ardizzone S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease.Dig Liver Dis. 2017;49:604-617. [PMID: 28254463 DOI: 10.1016/j.dld.2017.01.161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
422 Qiu Y, Chen B, Li Y, Xiong S, Zhang S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study. BMC Gastroenterol 2019;19:7. [PMID: 30630426 DOI: 10.1186/s12876-018-0928-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
423 van den Heuvel TRA, Jeuring SFG, Zeegers MP, van Dongen DHE, Wolters A, Masclee AAM, Hameeteman WH, Romberg-camps MJL, Oostenbrug LE, Pierik MJ, Jonkers DM. A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort—Can Diagnostic Factors Explain the Increase in IBD Incidence? Journal of Crohn's and Colitis 2017;11:1169-79. [DOI: 10.1093/ecco-jcc/jjx055] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
424 Bopanna S, Roy M, Das P, Dattagupta S, Sreenivas V, Mouli VP, Kedia S, Dhingra R, Pradhan R, Kumar NS, Yadav DP, Makharia G, Ahuja V. Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. Intest Res 2016;14:264-9. [PMID: 27433149 DOI: 10.5217/ir.2016.14.3.264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
425 Kedia S, Mouli VP, Kamat N, Sankar J, Ananthakrishnan A, Makharia G, Ahuja V. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2020;115:340-9. [DOI: 10.14309/ajg.0000000000000527] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
426 Gauss A, Geib T, Hinz U, Schaefert R, Zwickel P, Zawierucha A, Stremmel W, Klute L. Quality of Life Is Related to Fecal Calprotectin Concentrations in Colonic Crohn Disease and Ulcerative Colitis, but not in Ileal Crohn Disease. Medicine (Baltimore). 2016;95:e3477. [PMID: 27100452 DOI: 10.1097/md.0000000000003477] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
427 Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, Ferrante M, Van Assche G, Van der Merwe S, Vermeire S, Raes J. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65:1681-1689. [PMID: 27207975 DOI: 10.1136/gutjnl-2015-311004] [Cited by in Crossref: 183] [Cited by in F6Publishing: 164] [Article Influence: 30.5] [Reference Citation Analysis]
428 Reinisch W, Gottlieb K, Colombel J, Danese S, Panaccione R, Panes J, Peyrin-biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B. Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. Clinical Gastroenterology and Hepatology 2019;17:1673-1679.e1. [DOI: 10.1016/j.cgh.2018.10.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
429 Tontini GE, Pastorelli L, Spina L, Fabris F, Bruni B, Clemente C, de Nucci G, Cavallaro F, Marconi S, Neurath MF. Microscopic colitis and colorectal neoplastic lesion rate in chronic nonbloody diarrhea: a prospective, multicenter study. Inflamm Bowel Dis. 2014;20:882-891. [PMID: 24681653 DOI: 10.1097/mib.0000000000000030] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
430 Klotz C, Barret M, Dhooge M, Oudjit A, Chaussade S, Coriat R, Abitbol V. [Management of diagnosis and treatment in ulcerative colitis]. Presse Med 2015;44:144-9. [PMID: 25534469 DOI: 10.1016/j.lpm.2014.06.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
431 Xu Z, Wei B, Qiu Y, Zhang T. Altered Salivary Alpha-Amylase Secretion in Patients with Ulcerative Colitis. Gastroenterol Res Pract 2018;2018:4203737. [PMID: 29977288 DOI: 10.1155/2018/4203737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
432 Shi HY, Chan FK, Tsang SW, Hui YT, Sze SF, Ching JY, Chung T, Iu CY, Lo FH, Shan EH, Li MK, Wu JC, Sung JJ, Ng SC. Factors associated with mucosal healing in patients with ulcerative colitis in clinical remission. Inflamm Bowel Dis 2015;21:840-6. [PMID: 25738375 DOI: 10.1097/MIB.0000000000000334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
433 Sahami S, Konté K, Buskens CJ, Tanis PJ, Löwenberg M, Ponsioen CJ, van den Brink GR, Bemelman WA, D'Haens GR. Risk factors for proximal disease extension and colectomy in left-sided ulcerative colitis. United European Gastroenterol J 2017;5:554-62. [PMID: 28588887 DOI: 10.1177/2050640616679552] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
434 Voltes A, Bermúdez A, Rodríguez-gutiérrez G, Reyes ML, Olano C, Fernández-bolaños J, Portilla FDL. Anti-Inflammatory Local Effect of Hydroxytyrosol Combined with Pectin-Alginate and Olive Oil on Trinitrobenzene Sulfonic Acid-Induced Colitis in Wistar Rats. Journal of Investigative Surgery 2020;33:8-14. [DOI: 10.1080/08941939.2018.1469697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
435 Prieux-Klotz C, Dior M, Damotte D, Dreanic J, Brieau B, Brezault C, Abitbol V, Chaussade S, Coriat R. Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. Target Oncol 2017;12:301-8. [PMID: 28540478 DOI: 10.1007/s11523-017-0495-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
436 Freire P, Figueiredo P, Cardoso R, Donato MM, Ferreira M, Mendes S, Silva MR, Cipriano A, Ferreira AM, Vasconcelos H. Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? A randomized trial. Inflamm Bowel Dis. 2014;20:2038-2045. [PMID: 25185683 DOI: 10.1097/mib.0000000000000176] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 2.9] [Reference Citation Analysis]
437 Yadav DP, Kedia S, Madhusudhan KS, Bopanna S, Goyal S, Jain S, Vikram NK, Sharma R, Makharia GK, Ahuja V. Body Composition in Crohn's Disease and Ulcerative Colitis: Correlation with Disease Severity and Duration.Can J Gastroenterol Hepatol. 2017;2017:1215035. [PMID: 29226115 DOI: 10.1155/2017/1215035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
438 Mesonero F, Juliá B, Saldaña R, Savini C, Cañas M, Cea-Calvo L, Feo-Lucas L, Fernández S, Rodríguez-Lago I; ACCU, GETECCU and GETEII. Self-medication with oral corticosteroids reported by patients with ulcerative colitis: characteristics, reasons and patients' behaviors. Eur J Gastroenterol Hepatol 2021;33:501-7. [PMID: 32956185 DOI: 10.1097/MEG.0000000000001931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
439 Lobatón T, Azuara D, Rodríguez-Moranta F, Loayza C, Sanjuan X, de Oca J, Fernández-Robles A, Guardiola J, Capellá G. Relationship between methylation and colonic inflammation in inflammatory bowel disease. World J Gastroenterol 2014; 20(30): 10591-10598 [PMID: 25132780 DOI: 10.3748/wjg.v20.i30.10591] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
440 Aceituno M, Zabana Y, Esteve M. [Treatment of severe ulcerative colitis flares]. Gastroenterol Hepatol 2014;37:471-9. [PMID: 25015428 DOI: 10.1016/j.gastrohep.2014.05.005] [Reference Citation Analysis]
441 Gerçeker E, Yüceyar H, Kasap E, Demirci U, Ekti BC, Aydoğdu İ, Miskioğlu M. Treatment of inflammatory bowel disease by leukocytapheresis. Transfus Apher Sci 2017;56:421-6. [PMID: 28454883 DOI: 10.1016/j.transci.2017.03.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
442 Meng Q, Wu W, Pei T, Xue J, Xiao P, Sun L, Li L, Liang D. miRNA-129/FBW7/NF-κB, a Novel Regulatory Pathway in Inflammatory Bowel Disease. Mol Ther Nucleic Acids 2020;19:731-40. [PMID: 31945730 DOI: 10.1016/j.omtn.2019.10.048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
443 Uzzan M, Kirchgesner J, Oubaya N, Amiot A, Gornet J, Seksik P, Nancey S, Cotte E, Allez M, Boschetti G, Laharie D, de Angelis N, Nachury M, Pelletier A, Abitbol V, Fumery M, Brouquet A, Buisson A, Altwegg R, Cosnes J, Panis Y, Treton X. Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. Journal of Crohn's and Colitis 2017;11:930-5. [DOI: 10.1093/ecco-jcc/jjx027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
444 Amezaga AJ, Van Assche G. Practical Approaches to "Top-Down" Therapies for Crohn's Disease. Curr Gastroenterol Rep 2016;18:35. [PMID: 27184044 DOI: 10.1007/s11894-016-0507-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
445 Eberhardson M, Hedin CRH, Carlson M, Tarnawski L, Levine YA, Olofsson PS. Towards improved control of inflammatory bowel disease. Scand J Immunol 2019;89:e12745. [DOI: 10.1111/sji.12745] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
446 Huoponen S, Eberl A, Räsänen P, Roine RP, Sipponen T, Arkkila P, Blom M. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore) 2020;99:e18723. [PMID: 31914087 DOI: 10.1097/MD.0000000000018723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Gibson DJ, Hartery K, Doherty J, Nolan J, Keegan D, Byrne K, Martin ST, Buckley M, Sheridan J, Horgan G, Mulcahy HE, Cullen G, Doherty GA. CRP/Albumin Ratio: An Early Predictor of Steroid Responsiveness in Acute Severe Ulcerative Colitis. J Clin Gastroenterol 2018;52:e48-52. [PMID: 28737646 DOI: 10.1097/MCG.0000000000000884] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
448 Kamat N, Ganesh Pai C, Surulivel Rajan M, Kamath A. Cost of Illness in Inflammatory Bowel Disease. Dig Dis Sci. 2017;62:2318-2326. [PMID: 28766243 DOI: 10.1007/s10620-017-4690-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
449 Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: Results of a Delphi study among patients and physicians. Digestive and Liver Disease 2016;48:1172-9. [DOI: 10.1016/j.dld.2016.06.036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
450 Bergemalm D, Kruse R, Sapnara M, Halfvarson J, Hörnquist EH. Elevated fecal peptidase D at onset of colitis in Galphai2-/- mice, a mouse model of IBD. PLoS One 2017;12:e0174275. [PMID: 28323866 DOI: 10.1371/journal.pone.0174275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
451 Quénéhervé L, David G, Bourreille A, Hardouin JB, Rahmi G, Neunlist M, Brégeon J, Coron E. Quantitative assessment of mucosal architecture using computer-based analysis of confocal laser endomicroscopy in inflammatory bowel diseases. Gastrointestinal Endoscopy 2019;89:626-36. [DOI: 10.1016/j.gie.2018.08.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
452 Gupta A, Bopanna S, Kedia S, Yadav DP, Goyal S, Jain S, Makharia G, Ahuja V. Familial aggregation of inflammatory bowel disease in patients with ulcerative colitis. Intest Res 2017;15:388-94. [PMID: 28670236 DOI: 10.5217/ir.2017.15.3.388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
453 Dai C, Jiang M, Sun MJ, Cao Q. Fecal Lactoferrin for Assessment of Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019;. [PMID: 30994521 DOI: 10.1097/mcg.0000000000001212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
454 Atkinson NS, Bryant RV, Dong Y, Maaser C, Kucharzik T, Maconi G, Asthana AK, Blaivas M, Goudie A, Gilja OH. WFUMB Position Paper. Learning Gastrointestinal Ultrasound: Theory and Practice. Ultrasound Med Biol. 2016;42:2732-2742. [PMID: 27742140 DOI: 10.1016/j.ultrasmedbio.2016.08.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
455 Gagnière C, Bourrier A, Seksik P, Gornet J, Dewit O, Nancey S, Altwegg R, Abitbol V, Laharie D, Reenaers C, Buisson A, Pariente B, Viennot S, Vuitton L, Stefanescu C, Marteau P, Bouguen G, Cosnes J, Amiot A; the GETAID INFOPRO study group. Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). Aliment Pharmacol Ther 2018;48:713-22. [DOI: 10.1111/apt.14926] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
456 Zhu Y, Yang S, Zhao N, Liu C, Zhang F, Guo Y, Liu H. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother 2021;138:111427. [PMID: 33706134 DOI: 10.1016/j.biopha.2021.111427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
457 Armuzzi A, Pugliese D, Nardone OM, Guidi L. Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab. Drug Des Devel Ther. 2013;7:289-296. [PMID: 23630414 DOI: 10.2147/dddt.s33197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
458 Jakobsson GL, Sternegård E, Olén O, Myrelid P, Ljung R, Strid H, Halfvarson J, Ludvigsson JF. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol 2017;52:216-21. [PMID: 27797278 DOI: 10.1080/00365521.2016.1246605] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 12.7] [Reference Citation Analysis]
459 Artom M, Czuber-Dochan W, Sturt J, Proudfoot H, Roberts D, Norton C. Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. Pilot Feasibility Stud 2019;5:145. [PMID: 31890258 DOI: 10.1186/s40814-019-0538-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
460 Magro F, Lopes S, Coelho R, Cotter J, Dias de Castro F, Tavares de Sousa H, Salgado M, Andrade P, Vieira AI, Figueiredo P. Accuracy of Faecal Calprotectin and Neutrophil Gelatinase B-associated Lipocalin in Evaluating Subclinical Inflammation in UlceRaTIVE Colitis-the ACERTIVE study. J Crohns Colitis. 2017;11:435-444. [PMID: 27664275 DOI: 10.1093/ecco-jcc/jjw170] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
461 Azzam NA, Aljebreen A, Almuhareb A, Almadi MA. Disability and quality of life before and during the COVID-19 outbreak: A cross-sectional study in inflammatory bowel disease patients. Saudi J Gastroenterol 2020;26:256-62. [PMID: 32415045 DOI: 10.4103/sjg.SJG_175_20] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
462 Smolinska A, Bodelier AG, Dallinga JW, Masclee AA, Jonkers DM, van Schooten FJ, Pierik MJ. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis. Aliment Pharmacol Ther 2017;45:1244-54. [PMID: 28239876 DOI: 10.1111/apt.14004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
463 Sturm EM, Radnai B, Jandl K, Stančić A, Parzmair GP, Högenauer C, Kump P, Wenzl H, Petritsch W, Pieber TR, Schuligoi R, Marsche G, Ferreirós N, Heinemann A, Schicho R. Opposing roles of prostaglandin D2 receptors in ulcerative colitis. J Immunol 2014;193:827-39. [PMID: 24929001 DOI: 10.4049/jimmunol.1303484] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
464 Yamamoto-furusho J, Gutiérrez-grobe Y, López-gómez J, Bosques-padilla F, Rocha-ramírez J. The Mexican consensus on the diagnosis and treatment of ulcerative colitis. Revista de Gastroenterología de México (English Edition) 2018;83:144-67. [DOI: 10.1016/j.rgmxen.2018.04.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
465 Kim S, Lee B, Zhang X, Park J, Lee S, Lee H. Adjunctive herbal medicine therapy for inflammatory bowel disease: A systematic review and meta-analysis. European Journal of Integrative Medicine 2017;12:12-22. [DOI: 10.1016/j.eujim.2017.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
466 Altomare A, Putignani L, Del Chierico F, Cocca S, Angeletti S, Ciccozzi M, Tripiciano C, Dalla Piccola B, Cicala M, Guarino MPL. Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota. Digestive and Liver Disease 2019;51:648-56. [DOI: 10.1016/j.dld.2018.11.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
467 Gordillo J, Cabré E, Garcia-Planella E, Ricart E, Ber-Nieto Y, Márquez L, Rodríguez-Moranta F, Ponferrada Á, Vera I, Gisbert JP, Barrio J, Esteve M, Merino O, Muñoz F, Domènech E; ENEIDA Project of the Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU). Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry. J Crohns Colitis 2015;9:1063-70. [PMID: 26351379 DOI: 10.1093/ecco-jcc/jjv145] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
468 Choi YS, Kim JK, Kim WJ. Clinical characteristics and prognosis of patients with ulcerative colitis that shows rectal sparing at initial diagnosis. World J Gastrointest Endosc 2021; 13(9): 407-415 [PMID: 34630890 DOI: 10.4253/wjge.v13.i9.407] [Reference Citation Analysis]
469 Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2020;7:49-55. [PMID: 32232203 DOI: 10.14744/nci.2018.78800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
470 Frontali A, Colombo F, Sampietro GM. Acute severe ulcerative colitis: How to reduce operating time under 150 min for emergency laparoscopic colectomy - A video vignette. Colorectal Dis 2021. [PMID: 34586696 DOI: 10.1111/codi.15928] [Reference Citation Analysis]
471 Tursi A, Mocci G, Faggiani R, Allegretta L, Valle ND, Medici A, Forti G, Franceschi M, Ferronato A, Gallina S, Grasso G, Larussa T, Luzza F, Lorenzetti R, Penna A, Rodino' S, Sebkova L, Lauria A, Piergallini S, Pranzo G, Scorza S, Zampaletta C, Picchio M, Elisei W. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers. Eur J Intern Med 2019;66:85-91. [PMID: 31208827 DOI: 10.1016/j.ejim.2019.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
472 Yang ZH, Liu F, Zhu XR, Suo FY, Jia ZJ, Yao SK. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis. World J Gastroenterol 2021; 27(24): 3609-3629 [PMID: 34239273 DOI: 10.3748/wjg.v27.i24.3609] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
473 Sarid O, Slonim-nevo V, Schwartz D, Friger M, Sergienko R, Pereg A, Vardi H, Chernin E, Singer T, Greenberg D, Odes S; on behalf of the Israel IBD Research Nucleus (IIRN). Differing Relationship of Psycho-Social Variables with Active Ulcerative Colitis or Crohn’s Disease. Int J Behav Med 2018;25:341-50. [DOI: 10.1007/s12529-018-9712-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
474 Wang X, Zhu Y, Zhang M, Hou J, Wang H, Jiang Y, Wang H, Gao P. The shifted balance between circulating follicular regulatory T cells and follicular helper T cells in patients with ulcerative colitis. Clin Sci (Lond) 2017;131:2933-45. [PMID: 29109300 DOI: 10.1042/CS20171258] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
475 Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borralho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn's and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7:827-851. [PMID: 23870728 DOI: 10.1016/j.crohns.2013.06.001] [Cited by in Crossref: 336] [Cited by in F6Publishing: 273] [Article Influence: 37.3] [Reference Citation Analysis]
476 Kedia S, Jain S, Goyal S, Bopanna S, Yadav DP, Sachdev V, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V. Potential of Fecal Calprotectin as an Objective Marker to Discriminate Hospitalized Patients with Acute Severe Colitis from Outpatients with Less Severe Disease. Dig Dis Sci 2018;63:2747-53. [PMID: 29948556 DOI: 10.1007/s10620-018-5157-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
477 Skuja V, Derovs A, Pekarska K, Rudzite D, Lavrinovica E, Piekuse L, Kempa I, Straume Z, Eglite J, Lejnieks A, Krumina A, Eliakim R. Gut colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae may increase disease activity in biologic-naive outpatients with ulcerative colitis: an interim analysis. Eur J Gastroenterol Hepatol 2018;30:92-100. [PMID: 29076938 DOI: 10.1097/MEG.0000000000000989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
478 Canavese G, Villanacci V, Sapino A, Rocca R, Daperno M, Suriani R, Maletta F, Cassoni P; Members of the Piedmont IBD Group. The diagnosis of inflammatory bowel disease is often unsupported in clinical practice. Dig Liver Dis 2015;47:20-3. [PMID: 25445404 DOI: 10.1016/j.dld.2014.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
479 Rufini S, Ciccacci C, Di Fusco D, Ruffa A, Pallone F, Novelli G, Biancone L, Borgiani P. Autophagy and inflammatory bowel disease: Association between variants of the autophagy-related IRGM gene and susceptibility to Crohn's disease. Digestive and Liver Disease 2015;47:744-50. [DOI: 10.1016/j.dld.2015.05.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
480 Andus T. Chronisch-entzündliche Darmerkrankungen: Wissenschaft heute – Standard morgen, Koloproktologie UPDATE 2015. coloproctology 2016;38:314-25. [DOI: 10.1007/s00053-015-0064-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
481 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
482 Shi HY, Chan FK, Leung WK, Li MK, Leung CM, Sze SF, Ching JY, Lo FH, Tsang SW, Shan EH, Mak LY, Lam BC, Hui AJ, Chow WH, Wong MT, Hung IF, Hui YT, Chan YK, Chan KH, Loo CK, Ng CK, Lao WC, Harbord M, Wu JC, Sung JJ, Ng SC. Low-dose azathioprine is effective in maintaining remission in steroid-dependent ulcerative colitis: results from a territory-wide Chinese population-based IBD registry. Therap Adv Gastroenterol. 2016;9:449-456. [PMID: 27366213 DOI: 10.1177/1756283x16643509] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
483 Yoon SM, Haritunians T, Chhina S, Liu Z, Yang S, Landers C, Li D, Ye BD, Shih D, Vasiliauskas EA, Ippoliti A, Rabizadeh S, Targan SR, Melmed GY, McGovern DPB. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. Inflamm Bowel Dis 2017;23:1382-93. [PMID: 28590340 DOI: 10.1097/MIB.0000000000001150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
484 Salama RM, Darwish SF, El Shaffei I, Elmongy NF, Fahmy NM, Afifi MS, Abdel-Latif GA. Morus macroura Miq. Fruit extract protects against acetic acid-induced ulcerative colitis in rats: Novel mechanistic insights on its impact on miRNA-223 and on the TNFα/NFκB/NLRP3 inflammatory axis. Food Chem Toxicol 2022;:113146. [PMID: 35595039 DOI: 10.1016/j.fct.2022.113146] [Reference Citation Analysis]
485 Biedermann L, Fournier N, Misselwitz B, Frei P, Zeitz J, Manser CN, Pittet V, Juillerat P, von Känel R, Fried M, Vavricka SR, Rogler G; for the Swiss Inflammatory Bowel Disease Cohort Study Group. High Rates of Smoking Especially in Female Crohn’s Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation—Data from the Swiss IBD Cohort Study. ECCOJC 2015;9:819-29. [DOI: 10.1093/ecco-jcc/jjv113] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
486 Singh B, Kedia S, Konijeti G, Mouli VP, Dhingra R, Kurrey L, Srivastava S, Pradhan R, Makharia G, Ahuja V. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype. Indian J Gastroenterol. 2015;34:43-50. [PMID: 25663290 DOI: 10.1007/s12664-015-0538-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
487 Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. J Crohns Colitis. 2015;9:846-852. [PMID: 26116558 DOI: 10.1093/ecco-jcc/jjv111] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
488 Exarchos G, Gklavas A, Metaxa L, Papaconstantinou I. Quality of life of ulcerative colitis patients treated surgically with proctocolectomy and J-pouch formation: a comparative study before surgery and after closure of the defunctioning ileostomy. Ann Gastroenterol 2018;31:350-5. [PMID: 29720861 DOI: 10.20524/aog.2018.0247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
489 Tosca Cuquerella J, Bosca-Watts MM, Anton Ausejo R, Tejedor Alonso S, Mora De Miguel F, Minguez Perez M. Amyloidosis in Inflammatory Bowel Disease: A Systematic Review of Epidemiology, Clinical Features, and Treatment. J Crohns Colitis 2016;10:1245-53. [PMID: 27056947 DOI: 10.1093/ecco-jcc/jjw080] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
490 Ryu DG, Kim HW, Park SB, Kang DH, Choi CW, Kim SJ, Nam HS. Assessment of disease activity by fecal immunochemical test in ulcerative colitis. World J Gastroenterol 2016; 22(48): 10617-10624 [PMID: 28082814 DOI: 10.3748/wjg.v22.i48.10617] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
491 Walsh AJ, Bryant RV, Travis SP. Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol. 2016;13:567-579. [PMID: 27580684 DOI: 10.1038/nrgastro.2016.128] [Cited by in Crossref: 90] [Cited by in F6Publishing: 84] [Article Influence: 15.0] [Reference Citation Analysis]
492 Olivieri I, Cantini F, Castiglione F, Felice C, Gionchetti P, Orlando A, Salvarani C, Scarpa R, Vecchi M, Armuzzi A. Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. Autoimmun Rev. 2014;13:822-830. [PMID: 24726868 DOI: 10.1016/j.autrev.2014.04.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
493 Chen X, Hou J, Yuan Y, Huang C, Liu T, Mo C, Li H, Chen B, Xu Q, Hou Z, He W, Liu F. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis. BioDrugs 2016;30:207-17. [PMID: 27120055 DOI: 10.1007/s40259-016-0173-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
494 Jovanovic M, Gajovic N, Zdravkovic N, Jovanovic M, Jurisevic M, Vojvodic D, Maric V, Arsenijevic A, Jovanovic I. Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma. Mediators Inflamm. 2018;2018:8031328. [PMID: 29849497 DOI: 10.1155/2018/8031328] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
495 Sirin S, Kathemann S, Schweiger B, Hahnemann ML, Forsting M, Lauenstein TC, Kinner S. Magnetic resonance colonography including diffusion-weighted imaging in children and adolescents with inflammatory bowel disease: do we really need intravenous contrast? Invest Radiol. 2015;50:32-39. [PMID: 25215934 DOI: 10.1097/rli.0000000000000092] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
496 Sahu P, Vuyyuru SK, Kante B, Agarwal A, Sharma R, Das P, Panwar R, Jain S, Bopanna S, Makharia G, Kedia S, Ahuja V. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. Indian J Gastroenterol 2020;39:388-97. [PMID: 32880844 DOI: 10.1007/s12664-020-01043-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
497 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
498 Hicks LC, Huang J, Kumar S, Powles ST, Orchard TR, Hanna GB, Williams HR. Analysis of Exhaled Breath Volatile Organic Compounds in Inflammatory Bowel Disease: A Pilot Study. J Crohns Colitis 2015;9:731-7. [PMID: 26071410 DOI: 10.1093/ecco-jcc/jjv102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
499 Bossuyt X, Cohen Tervaert JW, Arimura Y, Blockmans D, Flores-Suárez LF, Guillevin L, Hellmich B, Jayne D, Jennette JC, Kallenberg CGM, Moiseev S, Novikov P, Radice A, Savige JA, Sinico RA, Specks U, van Paassen P, Zhao MH, Rasmussen N, Damoiseaux J, Csernok E. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017;13:683-92. [PMID: 28905856 DOI: 10.1038/nrrheum.2017.140] [Cited by in Crossref: 159] [Cited by in F6Publishing: 113] [Article Influence: 31.8] [Reference Citation Analysis]
500 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
501 Tursi A, Elisei W, Picchio M, Penna A, Lecca PG, Forti G, Giorgetti G, Faggiani R, Zampaletta C, Pelecca G. Managing ambulatory ulcerative colitis patients with infliximab: a long term follow-up study in primary gastroenterology centers. Eur J Intern Med. 2014;25:757-761. [PMID: 25086677 DOI: 10.1016/j.ejim.2014.07.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
502 Jain S, Kedia S, Bopanna S, Yadav DP, Goyal S, Sahni P, Pal S, Dash NR, Makharia G, Travis SPL, Ahuja V. Are Truelove and Witts criteria for diagnosing acute severe colitis relevant for the Indian population? A prospective study. Intest Res 2018;16:69-74. [PMID: 29422800 DOI: 10.5217/ir.2018.16.1.69] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
503 Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D’hoore A. Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. Journal of Crohn's and Colitis 2017;11:1353-61. [DOI: 10.1093/ecco-jcc/jjx095] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
504 Daniluk J, Daniluk U, Reszec J, Rusak M, Dabrowska M, Dabrowski A. Protective effect of cigarette smoke on the course of dextran sulfate sodium-induced colitis is accompanied by lymphocyte subpopulation changes in the blood and colon. Int J Colorectal Dis 2017;32:1551-9. [PMID: 28812128 DOI: 10.1007/s00384-017-2882-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
505 Park SH, Yang SK, Hong SM, Park SK, Kim JW, Lee HJ, Yang DH, Jung KW, Kim KJ, Ye BD. Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci. 2013;58:3592-3599. [PMID: 23979435 DOI: 10.1007/s10620-013-2828-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
506 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
507 Schulze H, Esters P, Hartmann F, Stein J, Christ C, Zorn M, Dignass A. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scand J Gastroenterol 2018;53:670-6. [PMID: 29560811 DOI: 10.1080/00365521.2018.1452974] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
508 Marinelli C, Savarino EV, Marsilio I, Lorenzon G, Gavaruzzi T, D'Incà R, Zingone F. Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors - A cross-sectional study. Sci Rep 2020;10:507. [PMID: 31949257 DOI: 10.1038/s41598-020-57460-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
509 Ballester MP, Martí D, Tosca J, Bosca-watts MM, Sanahuja A, Navarro P, Pascual I, Antón R, Mora F, Mínguez M. Disease severity and treatment requirements in familial inflammatory bowel disease. Int J Colorectal Dis 2017;32:1197-205. [DOI: 10.1007/s00384-017-2791-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
510 Jang HM, Baek HS, Kim JE, Kim JY, Lee YH, Cho HY, Choe YH, Kang B, Choe BH, Choi BS, Cho MH. Renal involvement in children and adolescents with inflammatory bowel disease. Korean J Pediatr 2018;61:327-31. [PMID: 30304912 DOI: 10.3345/kjp.2018.06485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
511 Assa A, Avni I, Ben-bassat O, Niv Y, Shamir R. Practice Variations in the Management of Inflammatory Bowel Disease Between Pediatric and Adult Gastroenterologists. Journal of Pediatric Gastroenterology & Nutrition 2016;62:372-7. [DOI: 10.1097/mpg.0000000000000943] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
512 Navas-lópez VM, Blasco-alonso J, Girón Fernández-crehuet F, Serrano Nieto MJ, Gallego-gutiérrez S, Luque Pérez S, Sierra Salinas C. Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. Clin J Gastroenterol 2014;7:320-3. [DOI: 10.1007/s12328-014-0506-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
513 Lu M, Zhang T, Lu Z, Wang W, Chen T, Cao Z. A comparison of the efficacy and safety of complementary and alternative therapies for ulcerative colitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21219. [PMID: 32664174 DOI: 10.1097/MD.0000000000021219] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
514 Weng MT, Tung CC, Lee YS, Leong YL, Shieh MJ, Shun CT, Wang CY, Wong JM, Wei SC. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study. BMC Gastroenterol. 2017;17:28. [PMID: 28193173 DOI: 10.1186/s12876-017-0586-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
515 Olaisen M, Rydning A, Martinsen TC, Nordrum IS, Mjønes P, Fossmark R. Cytomegalovirus infection and postoperative complications in patients with ulcerative colitis undergoing colectomy. Scandinavian Journal of Gastroenterology 2014;49:845-52. [DOI: 10.3109/00365521.2014.929172] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]